1997
- Peptimmune Collaborators at Harvard Demonstrate Linked Peptide Antigens Can 'Superactivate' Immune Response; PNAS Reports; Peptimer(TM) Technology is Platform for New Autoimmune, Viral Disease Treatments
- PR Newswire; Tuesday December 23, 8:29 am EST
- CAMBRIDGE, Mass., Dec. 23 /PRNewswire/ -- Researchers at Harvard University have demonstrated that the ability of certain peptide antigens to activate the immune system can be dramatically increased when delivered as oligomers -- repeating peptide antigens joined by specific peptide linkers. The laboratory studies, pub
- Interferon Sciences Commences Phase 2 Clinical Trial in Patients Co-Infected With HIV and Hepatitis C
- PR Newswire; Friday December 19, 11:56 am EST
- NEW BRUNSWICK, N.J., Dec. 19 /PRNewswire/ -- Interferon Sciences, Inc. (ISI) (Nasdaq-NNM: IFSC - news) announced today that patient enrollment has commenced in a multi-center, open label, Phase 2 clinical trial designed to evaluate the safety and efficacy of ALFERON N Injection in patients co-infected with HIV and hepa
- Gene Therapy for HIV to Get First Test in Humans; Enzo Therapeutics Files IND with FDA for Testing at University of California, San Francisco
- PR Newswire; Thursday December 18, 9:18 am EST
- FARMINGDALE, N.Y., Dec. 18 /PRNewswire/ -- Enzo Biochem (Amex: ENZ - news) announced today that its wholly owned subsidiary, Enzo Therapeutics, filed an Investigational New Drug (IND) application with the Food and Drug Administration ( FDA ) to initiate clinical testing, for the first time, of Enzo s new form of gene t
- DuPont Merck Broadens Expanded Access Program for Sustiva (efavirenz) -- HIV/AIDS Patients With Less Than 400 CD4 cells/mm3 Now Have Access to Sustiva
- PR Newswire; Wednesday December 17, 12:52 pm EST
- WILMINGTON, Del., Dec. 17 /PRNewswire/ -- The DuPont Merck Pharmaceutical Company announced today broadened access to the Sustiva (TM) ( efavirenz ) Expanded Access Program in the United States . Due to increased supply of drug, this change is occurring one month a
- Sheffield Pharmaceuticals Announces Agreement for HIV/AIDS RBC-CD4 Technology
- PR Newswire; Wednesday December 17, 8:48 am EST
- ST. LOUIS, Dec. 17 /PRNewswire/ -- Sheffield Pharmaceuticals, Inc. (Amex: SHM - news) announced that the Company has signed an option agreement with a private investment group that had a prior interest in the technology, to sell the Company s rights in its HIV/AIDS therapy, RBC-CD4. As consideration for the option, the
- AIDS Vaccine Program at St. Jude Children's Research Hospital Wins FDA Approval for Phase I Safety Trial; St. Jude Pediatric AIDS Program One of the Most Respected in the Nation
- PR Newswire; Tuesday December 16, 1:23 pm EST
- MEMPHIS, Tenn., Dec. 16 /PRNewswire/ -- Best known for improving the cure rate for children with leukemia severalfold since opening its doors 35 years ago, St. Jude Children s Research Hospital recently received FDA approval to safety test its unique AIDS vaccine. Dubbed the St. Jude multi-envelope AIDS vaccine, it is
- 'Hematologic Manifestations of HIV Disease' Educational Program Debuts On-Line: First-of-Its-Kind Program Provides Up-to-the-Minute Information About Critical, Relatively Ignored Area of AIDS Care
- PR Newswire; Tuesday December 16, 11:45 am EST
- POTOMAC, Md., Dec. 16 /PRNewswire/ -- Clinical insights and in-depth information about the hematologic manifestations of HIV disease are now available on-line at www.healthcg.com, a cutting-edge medical web site produced by Healthcare Communications Group, L.L.C. (HCG). Hematologic Manifestations of HIV is the newest i
- AIDS Vaccine Effective in Animal Tests; Human HGP-30 Antibodies Shown to Recognize HIV Subtypes
- PR Newswire; Wednesday December 10, 8:31 am EST
- ABIDJAN, Ivory Coast , Dec. 10 /PRNewswire/ -- Two studies presented here today at The 10th International Conference on AIDS and STDs in Africa have shown that an AIDS vaccine developed by CEL-SCI Corp., of Alexandria, Va., demonstrated protection against HIV infection in animals, and causes humans to produce antibodie
- HCFA Establishes Reimbursement For Digene's HPV Test
- PR Newswire; Tuesday December 9, 7:30 am EST
- BELTSVILLE, Md., Dec. 9 /PRNewswire/ -- Digene Corporation (Nasdaq: DIGE - news) announced today that the Health Care Financing Administration (HCFA), administrator for Medicaid and Medicare, has established reimbursement payment amounts for human papillomavirus (HPV) testing that will take effect January 1, 1998. Dige
- SunPharm Corp. Reports 80% Response Rate in Phase II Clinical Trial for Treatment of Aids-Related Diarrhea; New Compound Targets Condition Suffered by More Than 25% of AIDS Patients
- PR Newswire; Tuesday December 9, 9:09 am EST
- JACKSONVILLE, Fla., Dec. 9 /PRNewswire/ -- SunPharm Corporation (Nasdaq: SUNP - news) reported statistically significant results of a Phase II, multicenter clinical trial with Diethylhomospermine (DEHOP) in AIDS patients with uncontrolled, refractory diarrhea. Results from the trial demonstrated an overall response rat
- Interferon Sciences Completes Phase 3 Trial of HIV-Positive Patients
- PR Newswire; Monday December 8, 1:44 pm EST
- NEW BRUNSWICK, N.J., Dec. 8 /PRNewswire/ -- Interferon Sciences, Inc. (ISI) (Nasdaq: IFSC - news) announced today it has completed its Phase 3 clinical trial investigating the safety and efficacy of ALFERON N Injection(R) for the treatment of HIV-positive patients. This is an important milestone for ISI, said Lawrence
- Simplex Medical Systems, Inc. Receives Notification From Spain and Initial Order from Costa Rica
- PR Newswire; Monday December 8, 12:04 pm EST
- HALLANDALE, Fla., Dec. 8 /PRNewswire/ -- Simplex Medical Systems, Inc. (OTC Bulletin Board: SMLX - news) announced today that they have received notification from Spain s Ministry of Health, which allows for the importation of the Simplex Rapid HIV Saliva Test(TM), Simplex Rapid Saliva Test(TM) for Hepatitis, Simplex P
- Los Angeles AIDS Advocates Chastise Clinton Backsliding on Medicaid
- PR Newswire; Friday December 5, 8:47 pm EST
- LOS ANGELES, Dec. 5 /PRNewswire/ -- The nation s largest AIDS organization today sharply chastised the Clinton Administration for abandoning a proposed extension of Medicaid benefits to all persons infected with HIV. The Administration s splashy April announcement expressed its wish to extend benefits to the poor with
- Female Condom Launched In Brazil
- PR Newswire; Friday December 5, 8:00 am EST
- CHICAGO, Dec. 5 /PRNewswire/ -- The Female Health Company (Amex: FHC - news) reported that the Female Condom contraceptive was launched to the public sector in Brazil on World AIDS Day, December 1, 1997, by DKT do Brasil. The commercial sector launch will occur in January, 1998. DKT do Brasil markets male condoms in Br
- Medizone Signs Letters of Intent to Commence Human HIV/AIDS Clinical Trials in Europe; Improved Ozone Technology Delivery System to Enhance Market Potential
- PR Newswire; Tuesday December 2, 7:36 am EST
- SALT LAKE CITY, Dec. 2 /PRNewswire/ -- Medizone International, Inc. (Bulletin Board: MZEI.U) ( Medizone ) announced today that it will begin an aggressive clinical trial program in Italy during the second quarter of 1998, with an in-vitro study for viralcidal and dose-ranging activity. The initial Phase I trial conduct
- Peptimmune Acquires Option to HIV Therapeutic Vaccine Technology From Massachusetts General Hospital; Technology Based on Findings Published in Nov. 21, 1997 Issue of Science
- PR Newswire; Tuesday December 2, 8:29 am EST
- CAMBRIDGE, Mass., Dec. 2 /PRNewswire/ -- Peptimmune, Inc. announced today that it has acquired an exclusive option to license patent-pending technology from the Massachusetts General Hospital (MGH) related to a potential treatment for human immunodeficiency virus (HIV), the virus that causes AIDS. The technology is bas
- Elizabeth Glaser Pediatric AIDS Foundation Announces National Spokesperson -- Mary Steenburgen; Actress Mary Steenburgen Accepts Position to Draw Attention to the Work Started By Her Friend, Elizabeth Glaser -- Issues Critical to Pediatric HIV/AIDS
- PR Newswire; Monday December 1, 12:00 pm EST
- SANTA MONICA, Calif., Dec. 1 /PRNewswire/ -- The Elizabeth Glaser Pediatric AIDS Foundation announces the appointment of Mary Steenburgen as the Foundation s national spokesperson. Mary will officially begin her role today at an event commemorating Worlds AIDS Day. We are thrilled that Mary has stepped forward to accep
- The Elizabeth Glaser Pediatric AIDS Foundation Commemorates World AIDS Day and Presents First `Commitment to Children Award' to First Lady Hillary Rodham Clinton Event Focusing On Children Held Today In Washington, D.C.
- PR Newswire; Monday December 1, 12:00 pm EST
- WASHINGTON, Dec. 1 /PRNewswire/ -- With the theme of 1997 World AIDS Day, Give Children Hope In A World With AIDS, drawing national attention to the issue of pediatric HIV/AIDS, the Elizabeth Glaser Pediatric AIDS Foundation hosted a special World AIDS Day event today at the National Theatre in Washington, D.C. More ch
- Americans' Concern About HIV/AIDS Not Translating To Safer Sex Behavior; Durex Global AIDS Survey Reveals Only 13 percent of Americans Use Condoms During Every Sexual Encounter
- PR Newswire; Friday November 28, 4:00 am Eastern Time
- ATLANTA, Nov. 28 /PRNewswire/ -- Ninety-six percent of Americans are aware of HIV/AIDS and 65 percent worry about becoming infected with the virus, yet 44 percent still have not modified their sexual behavior to protect themselves, according to the results of the Durex Global AIDS Survey released today. Of the 56 perce
- World AIDS Day Global Fact Sheet; Statistics From the 1997 Report on the Global HIV/AIDS Epidemic UNAIDS and WHO
- PR Newswire; Wednesday November 26, 12:32 pm Eastern Time
- GENEVA, Nov. 26 /PRNewswire/ -- As you plan coverage and editorial in recognition of World AIDS Day, Monday, December 1, following are the latest estimates from UNAIDS and WHO on the global HIV/AIDS epidemic. -- There are 30.6 million people living with HIV/AIDS today. By the year 2000, a total of 40 million people wil
- Hard Candy Gives 'LOVE' to AIDS Organization
- PR Newswire; Wednesday November 26, 5:20 am Eastern Time
- BEVERLY HILLS, Calif., Nov. 26 /PRNewswire/ -- With WORLD AIDS DAY just around the corner on December 1st, hopefully more people will be talking and doing something in the fight against AIDS. Hard Candy founder and creator, Dineh Mohajer, is a strong supporter of the cause. To lend her help, Dineh has designed a nail p
- World AIDS Day: Condom Maker Advocates Fun, Safety and Responsible Choices
- PR Newswire; Wednesday November 26, 5:20 am Eastern Time
- EATONTOWN, N.J., Nov. 26 /PRNewswire/ -- On World AIDS Day, Ansell Personal Products, manufacturer of LifeStyles condoms, is introducing its Xtra Pleasure(TM) condom with a unique shape designed to enhance the tactile sensation of condom use. The condom s baggy shape, with extra room at the tip, is less restricting, pr
- VA Observes 'World AIDS Day' with Recommitment to Care, Research
- PR Newswire; Tuesday November 25, 12:25 pm Eastern Time
- WASHINGTON, Nov. 25 /PRNewswire/ -- The Department of Veterans Affairs (VA) will mark the international observance of World AIDS Day on Dec. 1 with a renewed commitment to caring for HIV-infected persons and a quest for advances through research. VA is recognized as a leader in the study and state-of-the-art treatment
- Congresswoman Maxine Waters Announces $1 Million Federal Allocation For Innovative New AIDS Treatment Program in Los Angeles; AIDS Healthcare Foundation to Launch S.T.A.R.T. Program - Success Through Anti-Retroviral Treatment to Maximize Adherence to AIDS Meds
- PR Newswire, Tuesday November 25, 3:34 pm Eastern Time
- LOS ANGELES, Nov. 25 /PRNewswire/ -- In a ceremony heralding a potentially brighter new beginning for many of those living with HIV, Congresswoman Maxine Waters today announced allocation of $1 million in new federal funds earmarked for an aggressive and innovative new AIDS treatment initiative here in Los Angeles. At
- Genital Herpes - The Silent Epidemic
- PR Newswire; Friday November 21, 11:08 am Eastern Time
- LONDON, Nov. 21 /PRNewswire/ -- International medical experts will address the public health issues caused by the dramatic increase in genital herpes world-wide, highlighted by recent new data in the New England Journal of Medicine(1), at the annual meeting of the International Herpes Management Forum (IHMF) in Cannes,
- Los Angeles AIDS Summit Explores People of Color & HIV; Senator Art Torres (Ret) To Chair December 3rd Community Forum; Co-sponsored by AIDS Healthcare Foundation, Bienestar Latino AIDS Project and Minority AIDS Project
- PR Newswire; Friday November 14, 12:00 pm Eastern Time
- LOS ANGELES, Nov. 14 /PRNewswire/ -- The first Los Angeles AIDS Summit: People of Color and HIV conference convenes Wednesday December 3rd at the L.A. City Board of Education headquarters in Downtown Los Angeles from 10:00 a.m. to 12:00 noon. Senator Art Torres (Ret) will chair the AIDS Summit. It offers community lead
- Imutec Pharma Receives Support Of Canadian HIV Trials Network
- PR Newswire; Thursday November 13, 8:22 am Eastern Time
- TORONTO, Nov. 13 /CNW-PRN/ - Imutec Pharma Inc. announced today that it has received the support of the Canadian HIV Trials Network for the Company s Phase I/II clinical trial of Virulizin(R) in the treatment of human immunodeficiency virus ( HIV ) related Kaposi s sarcoma. The Canadian HIV Trials Network ( CTN ) is a
- Verex Laboratories Announces Issuance of U.S. Patent Associated With its Controlled Release AZT Product for HIV & AIDS
- PR Newswire; Wednesday November 12, 2:37 pm Eastern Time
- ENGLEWOOD, Colo., Nov. 12 /PRNewswire/ -- Verex Laboratories, Inc. (OTC Bulletin Board: VRXL - news) today announced that the United States Patent Office recently granted the Company patent number 5,681,581. This patent covers the use of Verex s novel controlled release drug delivery system for the administration of zi
- Reducing Substance Abuse in Our Communities: U.S. Government Publications and Products Available Online at NTIS
- PR Newswire; Thursday November 6 5:20 AM EST
- WASHINGTON, Nov. 6 /PRNewswire/ -- Substance abuse affects us all in one way or another. If a child or parent is an abuser, the whole family suffers. When families suffer, so does the community and our country. The cost of drugs and alcohol on our lives, on our resources, schools, and treatment facilities grows higher
- Progenics Pharmaceuticals Awarded $3.0 Million From The National Institutes of Health For Hiv Program
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday November 4 8:29 AM EST
- TARRYTOWN, N.Y., Nov. 4 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. today announced it has been awarded a total of approximately $3.0 million under three separate NIH programs for therapeutic and vaccine products in the Company s HIV program. The funding consists of four grants and one contract, all from the Nation
- Harris Poll: 71% of Americans Support Lifting Ban on Federal Funding for Needle Exchange Programs; States and Localities Should Decide How to Use Federal HIV Prevention Funds
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday October 31, 1997
- NEW YORK, Oct. 31 /PRNewswire/ -- Americans believe that cities and states -- and not the federal government -- should decide whether federal HIV prevention funds can be spent on needle exchange programs, according to a recent Harris poll commissioned by the Lindesmith Center. The poll, which surveyed 1,003 American ad
- Pennsylvania Approves Viracept for Its HIV/AIDS Drug Program
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday October 30 4:20 PM EST
- HARRISBURG, Pa., Oct. 30 /PRNewswire/ -- State Public Welfare Secretary Feather O. Houstoun today announced that effective Saturday, Nov. 1, the department will add viracept -- the latest protease inhibitor approved by the U.S. Food and Drug Administration ( FDA ) -- to its Special Pharmaceutical Benefits Program (SPBP
- International Murex Receives French Registration For New HIV 1+2+0 Screening Test: Highly Sensitive and Specific, Test Utilizes Patented Antigen Sandwich Technology
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday October 28 10:31 AM EST
- TORONTO, Oct. 28 /PRNewswire/ -- International Murex Technologies Corporation (Nasdaq:MURXF - news), today announced the Company has received French registration for its new HIV 1+2+0 screening test. Utilizing Murex s patented Antigen Sandwich Assay technology, the new test is extremely sensitive and specific and it no
- National AIDS Fund Survey Finds HIV-Positive Employees May Face Continuing Workplace Discrimination
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday October 28 8:26 AM EST
- WASHINGTON, Oct. 28 /PRNewswire/ -- Despite more than a decade of public education on AIDS, and federal laws that protect the rights of HIV-positive employees, more than 30 percent of employees recently polled by the National AIDS Fund said they believe an HIV-infected employee would be fired or placed on disability by
- Demeter BioTechnologies, Ltd. Announces Peptidyl MIMs(TM) Effective Against STD Pathogens
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday October 22 10:33 AM EDT
- DURHAM, N.C., Oct. 22 /PRNewswire/ -- Demeter BioTechnologies, Ltd. (OTC-Bulletin Board: DBOT) announces that its compound Peptidyl MIM(TM) D2A21 is effective in vitro, at low concentrations, in killing a number of microorganisms that cause sexually transmitted diseases (STDs), including: Neisseria gonorrhoeae, Trichom
- Female Condom Launched In Canada
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday October 21 8:31 AM EDT
- CHICAGO, Oct. 21 /PRNewswire/ -- The Female Health Company (AMEX:FHC) reported that the Reality(R) female condom has been launched by Montreal-based Pharmascience and is now available to Canadian women and their partners throughout the country. The addition of Canada to the growing list of countries where the female co
- Medizone International To Move Forward With Human Clinical Trials
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday October 21 8:15 AM EDT
- SALT LAKE CITY, Oct. 21 /PRNewswire -- Medizone International, Inc. (OTC-Bulletin Board: MZEI.U) ( Medizone ), announced today it has reached an agreement in principle to commence Phase I/II Human Clinical Trials at two prestigious Italian University sites using Medizone patented thin-film ozone technology. The clinica
- AIDS Vaccine Program at St. Jude Children's Research Hospital Gets First Step FDA Approval -- Phase I Safety Trial to Get Underway
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday October 17 6:56 AM EDT
- MEMPHIS, Tenn, Oct. 17 /PRNewswire/ -- In the first step of a multi-tier AIDS vaccine development program at St. Jude Childrens Research Hospital, the Food and Drug Administration ( FDA ) has approved a Phase I safety trial of a new AIDS vaccine designed to trigger immune responses to multiple, differing isolates of HI
- New HIV/AIDS Treatment Sustiva (efavirenz) Clinical Results Promising In Combination with AZT and 3TC; Investigational, Once-Daily NNRTI in Combination Suppresses HIV In 88 Percent of Patients
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday October 13 2:35 PM EDT
- WILMINGTON, Del., Oct. 13 /PRNewswire/ -- The DuPont Merck Pharmaceutical Company announced today that Sustiva (TM) ( efavirenz ), its once-daily investigational anti-HIV medicine, has shown significant viral load reduction in patients receiving combination therapy not involving a protease inhibi
- Cell Genesys Scientists Report Killing of HIV-Infected Cells With T Cell Gene Therapy
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday October 13 5:00 PM EDT
- FOSTER CITY, Calif., Oct. 13 /PRNewswire/ -- Cell Genesys, Inc. (Nasdaq:CEGE) reported today that a team of company scientists has demonstrated early and efficient killing of human immunodeficiency virus (HIV)-infected cells in laboratory studies using immune system T cells which have been genetically engineered to see
- Wake Forest Scientists Find Way To Short-Circuit Initial HIV Invasion
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday October 13 5:49 PM EDT
- WINSTON-SALEM, N.C., Oct. 13 /PRNewswire/ -- Scientists at Wake Forest University Baptist Medical Center report today that they have found another way to shut down the doorway for HIV-1 to invade two types of white blood cells -- lymphocytes and macrophages. In a report in the Oct 14 issue of the Proceedings of the Nat
- Vertex Pharmaceuticals Reports Encouraging Preliminary Data from Phase II Clinical Study with HIV Protease Inhibitor 141W94
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday October 13 8:29 AM EDT
- CAMBRIDGE, Mass., Oct. 13 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced for the first time preliminary 12 week data from an ongoing Phase II study of 141W94 (VX-478), an HIV protease inhibitor currently in Phase III clinical trials. The data, presented at the 6th European Conference
- Governor Wilson Vetoes SB 1035 Polanco-authored Bill Would Have Expanded MEDI-CAL Coverage to HIV Positive; Goal Was to Pull HIV Positive Californians into Treatment Lifeboat Before Onset of Full Disability: Polanco, AIDS Healthcare Foundation and Other Sponsors Vow to Re-introduce Bill in 1998
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday October 10 6:50 PM EDT
- LOS ANGELES, Oct. 10 /PRNewswire/ -- In a setback to HIV positive Californians and AIDS advocates throughout the state, Governor Pete Wilson yesterday vetoed Senate Bill 1035, legislation by Senator Richard Polanco (D, Los Angeles) that would have helped expand Medi-Cal eligibility to HIV positive Californians before t
- 'HIV/AIDS: Yesterday, Today, Tomorrow' Topic of MetroHealth Conference
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday October 8 8:02 AM EDT
- CLEVELAND, Oct. 8 /PRNewswire/ -- Nineteen-Ninety-Seven has been a watershed year in the relatively short history of HIV/AIDS in this country. For the first time, protease inhibitors have prolonged the lives of many for whom death seemed imminent. The introduction of new testing options has influenced the lives of many
- Aastrom Biosciences Awarded Two NIH Grants for Umbilical Cord Blood Transplants and AIDS Gene Therapy; Grants Support Development of New Applications for Aastrom's Enabling Technologies for the Transplantation and Gene Modification of Human Stem Cells
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday October 7 8:40 AM EDT
- ANN ARBOR, Mich., Oct. 7 /PRNewswire/ -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) announced today that it was awarded two grants from the National Institutes of Health (NIH), totaling approximately $460,000. A Phase I Small Business Innovation and Research (SBIR) grant, received from the National Heart, Lung and Blood I
- Comprehensive Summaries of 1997 ICAAC Sessions Now Available on World Wide Web; www.healthcg.com Features Highlights of Key HIV Presentations Plus Two Unique Satellite Symposia
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday October 1 11:50 AM EDT
- POTOMAC, Md, Oct. 1 /PRNewswire/ -- Next-morning summaries from the 1997 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) are now available on the world wide web at http://www.healthcg.com. The daily summaries, produced by Healthcare Communications Group (HCG) and written by leaders in the field
- Wake Forest Scientists Find Novel Way To Block AIDS Virus
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday October 1 12:37 PM EDT
- WINSTON-SALEM, N.C., Oct. 1 /PRNewswire/ -- Wake Forest University scientists today reported in Nature Medicine a novel way to block the deadly HIV virus from ever invading white blood cells. This new strategy is a fundamental new way to treat patients with HIV-1 infection or AIDS. This study, by Si.-Yi Chen, M.D., Ph.
- Los Angeles Proclaims October AIDS TREATMENT EQUALS LIFE Month: 50 Local Media Outlets Join AIDS Healthcare Foundation to Get Message Out About HIV Treatment and Testing, Raise Funds for Critical AIDS Services
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday October 1 3:29 PM EDT
- LOS ANGELES, Oct. 1 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the nation s largest HIV/AIDS medical provider, today proudly kicks off TREATMENT EQUALS LIFE Month, an October-long awareness and fundraising effort for AIDS treatment and outreach led by AHF. Over 50 Southern California media outlets including radi
- Combination CYTOVENE(R) Capsules and Implant Delays New Life- and Sight-Threatening Disease
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday October 1 4:57 PM EDT
- TORONTO, Oct. 1 /PRNewswire/ -- New data presented during a late-breaker session during the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Toronto, indicates that combining the Vitrasert (TM) implant and CYTOVENE(R) capsules (oral ganciclovir) reduces the incidence of
- Triangle Pharmaceuticals Reports Data on Increased Dosages of MKC-442 in HIV-Infected Patients; Data Presented at Annual ICAAC Meeting in Toronto
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday September 29 8:29 AM EDT
- DURHAM, N.C., Sept. 29 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq:VIRS) yesterday presented additional data on an ongoing clinical trial of MKC-442 at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Toronto, Canada . MKC-442 is a non-nucleoside reverse transcriptase inhibitor (NNRTI)
- SE Asia Studies Show Good Results for Saliva Diagnostic Systems' Rapid HIV Test--Vietnam and Malaysia studies compare Hema-Strip HIV to other widely-used HIV tests; New distribution partners in South America
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday September 29 8:12 AM EDT
- VANCOUVER, Wash.--(BUSINESS WIRE)--Sept. 29, 1997-- Studies recently completed by independent investigators in Malaysia and Vietnam using Hema-Strip HIV, a rapid whole blood test developed by Saliva Diagnostic Systems, Inc. (Nasdaq:SALV), indicate the device is equivalent in sensitivity and specificity to other, widely
- Visible Genetics Inc. Introduces HIV TruGene(TM), A Sequence-Based HIV Genotyping Research Product Line
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday September 29 7:00 AM EDT
- TORONTO, Sept. 29 /PRNewswire/ -- Visible Genetics Inc. (Nasdaq:VGINF) (VGI) today introduced HIV TruGene(TM), a new research product line for sequence-based genotyping of the human immunodeficiency virus (HIV). These HIV kits are the first to use VGI s recently introduced genotyping engine, the Clipper(TM), and CLIP,
- Agouron's VIRACEPT Exhibits Anti-HIV Potency After 12 Months Additional Results Reported at International Meeting
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday September 29 8:32 AM EDT
- LA JOLLA, Calif., Sept. 29 /PRNewswire/ -- Clinical investigators will report this week on additional studies of VIRACEPT(R) (nelfinavir mesylate), the HIV protease inhibitor marketed in the U.S. by Agouron Pharmaceuticals, Inc. (Nasdaq-NNM:AGPH). Reports will include data showing that anti-HIV effects from VIRACEPT, w
- New Studies with Crixivan Presented at ICAAC: Crixivan in Triple Therapy Lowered HIV to Undetectable Levels for Two Years in Approximately 80 Percent of Patients in Merck Study 035; In Preliminary Trial, Twice-Daily Dosing of Crixivan in Triple Therapy Suppressed HIV Below Detection in Most Patients; Large Study Underway
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday September 29 8:01 AM EDT
- TORONTO, Sept. 29 /PRNewswire/ -- Triple therapy with Crixivan (R) ( indinavir sulfate), Merck s HIV protease inhibitor, in combination with AZT (a) and 3TC (b), suppressed H
- New Tablet Combines the Two Most Commonly Prescribed Antiretroviral HIV Medications; Combination Therapy Simplified
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday September 29 8:34 AM EDT
- RESEARCH TRIANGLE PARK, N.C., Sept. 29 /PRNewswire/ -- A single tablet containing the two most widely used antiretroviral medications has been cleared for use by the Food and Drug Administration. This is the first major step toward simplifying highly effective HIV combination drug regimens, which for some people, are d
- Norvir (Ritonavir) With Nucleoside Analogues Results in More Children With Undetectable HIV (less than 400 Copies/Ml) Compared With Nucleoside Analogues Alone; Study Arm Without Norvir Closed
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday September 29 11:09 AM EDT
- TORONTO, Sept. 29 /PRNewswire/ -- A new study demonstrates that a significantly greater number of children receiving Abbott Laboratories (NYSE:ABT) Norvir ( ritonavir ), in combination either with stavudine (
- New HIV/AIDS Treatment Sustiva (efavirenz) Promising in Several Drug Combinations; Investigational, Once-Daily NNRTI Penetrates Patient Cerebrospinal Fluid
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday September 29 9:01 AM EDT
- TORONTO, Sept. 29 /PRNewswire/ -- The DuPont Merck Pharmaceutical Company today announced new findings from five studies of its investigational, non-nucleoside reverse transcriptase inhibitor (NNRTI) Sustiva (TM) (also referred to as efavirenz or DMP 266).
- Combination of Norvir and Invirase Suppresses HIV RNA Within the Central Nervous System (CNS); This study shows dual-protease therapy can bring HIV viral load to undetectable levels (less than 400 copies/mL) in CNS
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday September 29 11:31 AM EDT
- TORONTO, Sept. 29 /PRNewswire/ -- HIV RNA levels in the cerebrospinal fluid (CSF) were undetectable (less than 400 copies/mL) in 12 of 13 patients receiving Abbott Laboratories (NYSE:ABT) Norvir ( ritonavir ) and Hoffmann-La Roche s Invirase (saquinavir me
- AIDS Experts Examine New Data, Provide Insights on Putting HIV Treatment Guidelines Into Action; Symposium Probes First Comparison of Triple Combination Therapies and New Understanding of Resistance and Adherence Challenges
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday September 29 9:02 AM EDT
- TORONTO, Sept. 29 /PRNewswire/ -- Leading AIDS experts explored today new data and growing knowledge of how to use recent Federal guidelines to better treat HIV-infected patients over a longer period of time. At a symposium held at the start of a major scientific conference, researchers presented initial data on the fi
- Innovative Technology for Better Detection of HIV Granted U.S. Patent; New Product to Undergo U.S. Studies May Enhance Safety of World's Blood Supply
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday September 29 11:25 AM EDT
- REHOVOT, Israel , Sept. 29 /PRNewswire/ -- Shiloov Medical Technologies Ltd. announced today that it has been issued a U.S. patent that claims a method for the detection of HIV antibodies in whole blood samples. The issuance of this patent will help Shiloov protect its products, which enable the earlier and more accura
- Pediatric AIDS Foundation Supports New Pediatric HIV/AIDS Treatment Guidelines; Guidelines For the Use of Antiretroviral Agents in Pediatric HIV Infection
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday September 29 10:28 AM EDT
- SANTA MONICA, Calif., Sept. 29 /PRNewswire/ -- The Pediatric AIDS Foundation applauds the new treatment guidelines which will be posted in the Federal Register for public comment. The organization is now urging that more aggressive guidelines be established as soon as new data becomes available. Following the release o
- AIDS Experts Examine New Data, Provide Insights on Putting HIV Treatment Guidelines Into Action; Symposium Probes First Comparison of Triple Combination Therapies and New Understanding of Resistance and Adherence Challenges
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Sunday September 28 12:35 PM EDT
- TORONTO, Sept. 27 /PRNewswire/ -- Leading AIDS experts explored today new data and growing knowledge of how to use recent Federal guidelines to better treat HIV-infected patients over a longer period of time. At a symposium held at the start of a major scientific conference, researchers presented initial data on the fi
- HIV Patient Remains in Remission After Suspension of New Treatment
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday September 26 9:36 AM EDT
- WASHINGTON, Sept. 26 /PRNewswire/ -- A new combination of anti-viral drugs led to the early remission of HIV in a patient who had been infected with the virus for seven weeks, according to a news report in the Sept. 26 issue of Science. The patient went into remission during six months of treatment, and remains in remi
- VIRAMUNE Triple Combo Reduces Viral Load Below Limit of Detection In 60 Percent 0f Advanced-Stage HIV-1 Patients - 48 Week Data from Study ISS 047 Presented Today -
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday September 26 4:04 PM EDT
- ADVANCE/ TORONTO, Sept. 29 /PRNewswire/ -- Triple combination therapy using VIRAMUNE(R) ( nevirapine ) -- a non-nucleoside reverse transcriptase inhibitor (NNRTI) -- in combination with two nucleoside analogues, AZT (zidovudine) and ddI (didanosine), produced a significant viral load reduction i
- Researchers Study the Brain as a Viral Sanctuary for the HIV Virus; Satellite Symposium to Discuss Treatment Implications
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday September 26 4:07 PM EDT
- ADVANCE/ TORONTO, Sept. 26 /PRNewswire/ -- HIV-related dementia and other neurological disorders may be driven by uncontrolled viral replication occurring in the brain and spinal cord area, said AIDS experts today at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Justin McArthur,
- Viramune Triple Therapy Shows Suppression of HIV After One Year, 7 Months - Over 50% of Patients Below Limit of Detection
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday September 26 4:05 PM EDT
- ADVANCE/ TORONTO, Sept. 29 /PRNewswire/ -- Early initiation of the potent AIDS drug VIRAMUNE(R) ( nevirapine ) in combination with two nucleoside analogues can sustain plasma HIV RNA reductions below detectable levels (based on an experimental assay with a limit of 20 copies/mL). These results were presented today at t
- Elizabeth Taylor's First In-Depth Print Interview Since Surgery Will Appear in POZ, a Magazine for People with HIV/AIDS; Taylor Re-Asserts Commitment to AIDS Fight, Discusses Near-Death Experiences, Dishes Hollywood and the Betty Ford Center, and Blasts President Clinton for 'Waffling' on Needle Exchange
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday September 23 11:00 AM EDT
- NEW YORK, Sept. 23 /PRNewswire/ -- Elizabeth Taylor has given her first in-depth print interview since her recent surgery to POZ, a 100,000 circulation national monthly magazine for people affected by AIDS. The magazine hits subscriber mailboxes September 26 and appears on newsstands in early October. In the exclusive
- First-Ever HIV Treatment Guide for Women Launched by Women Alive; KNOWLEDGE, ACTION, HEALTH Encourages Empowerment Among HIV-Positive Women
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday September 19 11:20 AM EDT
- MIAMI, Sept. 19 /PRNewswire/ -- Women Alive, a national organization dedicated to women with HIV disease, today released KNOWLEDGE, ACTION, HEALTH - A Woman s Guide to HIV Treatments, the first-ever women s comprehensive HIV treatment guide. We must begin to make sense of confusing advice and missing data surrounding o
- CEL-SCI Corporation and AIDS ReSEARCH Alliance Announce Results of HGP-30 AIDS Vaccine Study, Plan Further Study
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday September 17 8:30 AM EDT
- ALEXANDRIA, Va., Sept. 17 /PRNewswire/ -- CEL-SCI CORPORATION (Amex:HIV) and AIDS ReSEARCH Alliance of West Hollywood, California, announce the completion of a phase I safety study of the HGP-30 AIDS vaccine in 24 HIV infected patients. The study showed that immunizations with the HGP-30 vaccine coupled to KLH were saf
- New Study Finds Investigational, Once-Daily HIV/AIDS Drug Sustiva (efavirenz) Has Long-Term Success with Protease Inhibitor Indinavir and Other Anti-HIV Drugs
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday September 16 3:01 PM EDT
- SAN FRANCISCO, Sept. 16 /PRNewswire/ -- The DuPont Merck Pharmaceutical Company today announced 48-week data from an ongoing Phase II study of its once-daily anti-HIV drug, Sustiva (TM) ( efavirenz ), in combination with indinavir .
- Improved HIV Therapies Are Emerging Due to Advances in Viral Load Testing Technologies; A New DR Reports Study Analyzes the Commercial Implications
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday September 15 8:59 AM EDT
- WALTHAM, Mass., Sept. 15 /PRNewswire/ -- Viral load testing has demonstrated the efficacy of emerging AIDS drugs. It is now known that combination therapies involving compounds such as protease inhibitors and non- nucleoside reverse transcriptase inhibitors (NNRTIs) are the key to reducing viral load. The development o
- New England Journal of Medicine Publishes Landmark AIDS Studies: In Studies, Crixivan(R) in Triple Therapy Kept HIV Below Detection in Most Patients; Fewer AIDS-Related Illnesses and Deaths Observed -- Most People with HIV Still Not Taking 3-Drug `Cocktail'
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday September 10 5:00 PM EDT
- WEST POINT, Pa., Sept. 10 /PRNewswire/ -- The New England Journal of Medicine today published studies that showed that Merck s (NYSE:MRK) protease inhibitor Crixivan (R) ( indinavir sulfate) taken with two other AIDS drugs reduced HIV in the blood to undetectable levels (less than 500 copies vRN
- Los Angeles Candlelight Vigil Set to Honor Princess Diana's AIDS Efforts Friday, September 5th 7:30 p.m.; Vigil Includes Candlelight March Along Santa Monica Blvd. from Crescent Heights Blvd. to San Vicente Blvd.; Signing of AIDS Quilt Panels in Her Honor for AIDS Memorial Quilt.
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday September 3 8:40 PM EDT
- LOS ANGELES, Sept. 3 /PRNewswire/ -- As a small, but heartfelt gesture of appreciation for Princess Diana s early and ongoing compassionate work on behalf of people with HIV and AIDS, AIDS Healthcare Foundation (AHF), the nation s largest HIV/AIDS medical provider, is coordinating an impromptu candlelight vigil and mar
- U.S. Patent Office Allows Patent to CEL-SCI Corporation on AIDS Diagnostic Kit
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday September 3 8:30 AM EDT
- ALEXANDRIA, Va., Sept. 3 /PRNewswire/ -- CEL-SCI Corporation (Amex:HIV) announces the allowance of a U.S. patent on the diagnostic method and test kit for the serological detection of the AIDS virus. The test kit is based upon the measurement of antibodies against a region (HGP-30) of the core of the AIDS virus. As par
- Digene Grants Murex European Distribution Rights To New HIV Viral Load, Cytomegalovirus and Hepatitis B Tests
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday September 3 10:44 AM EDT
- BELTSVILLE, Md., Sept. 3 /PRNewswire/ -- Digene Corporation (Nasdaq:DIGE) today announced that it has further extended the Company s strategic alliance with International Murex Technologies Corporation (Nasdaq:MURXF - news). Under a new distribution agreement, Murex will distribute Digene s new Hybrid Capture(R) II HIV
- Wyeth-Ayerst To Market ABELCET(R) In France and Italy for The Liposome Company
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday 27 Auguest 1997.
- PRINCETON, N.J., Aug. 27 /PRNewswire/ -- The Liposome Company, Inc. (Nasdaq: LIPO) today announced that Wyeth-Ayerst International, Inc., a division of American Home Products Corporation (NYSE: AHP), will be its marketing partner for ABELCET(R) in France and Italy . ABELCET is a p
- International Panretin(TM) Topical Gel Trial Demonstrates Positive Results in Kaposi's Sarcoma; Study Stopped
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday 26 August 1997.
- SAN DIEGO, Aug. 26 /PRNewswire/ -- An international Phase III pivotal trial of Panretin(TM) (9-cis-retinoic acid) Topical Gel in patients with AIDS-related Kaposi s sarcoma (KS) has been stopped early because an interim analysis permitted under the protocol showed a marked response to Panretin compared with placebo (ve
- American Red Cross and CEL-SCI Corporation Enter Into A Long-Term Supply Agreement
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 25 August 1997.
- ALEXANDRIA, Va., Aug. 25 /PRNewswire/ -- CEL-SCI CORPORATION (AMEX: HIV ) announces that is has reached a long-term supply agreement with the American Red Cross for the supply of human white blood cells (buffy coats) for the production of CEL-SCI s immune boosting product, Multikine(TM). We have enjoyed a very good rel
- Zerit(R) (stavudine) Approved For First-Line Treatment of HIV in Europe; Indication Includes Adults and Children
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday August 25 7:00 PM EDT
- PRINCETON, N.J., Aug. 25 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE:BMY) today announced that Zerit (R) ( stavudine ), also known as d4T , received approval by the European Union for use in combi
- Sanofi Diagnostics Pasteur Offers Laboratories Improved HIV-1/HIV-2 Test Licensed by U.S. Food & Drug Administration
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday August 25 2:05 PM EDT
- REDMOND, Wash., Aug. 25 /PRNewswire/ -- A new, improved version of a specific test for the detection of antibodies to both HIV-1 and HIV-2 viruses in human blood and plasma has been licensed by the U.S. Food and Drug Administration ( FDA ). It is being made available immediately to blood banks and testing laboratories
- AIDS Epidemic Could Have Been Prevented by Public Health Measures; Article in Medical Journal Blames Misinformation and Inaction by Organized Medicine: AIDS Experts Cross Swords in Debate
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday August 21 6:06 PM EDT
- CAUTION -- ADVANCE FOR RELEASE AT 12:01 A.M. MONDAY, AUG. 25/ WASHINGTON, Aug. 21 /PRNewswire/ -- The AIDS epidemic could have been prevented in the mid-80s if appropriate public health measures had been implemented, and the dissemination of misleading information and the efforts of the hierarchy of organized medicine
- FRC: Americans Overwhelmingly Oppose Needle Exchange Programs, Say Government Should Promote Drug Rehabilitation
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 20 August 1997.
- WASHINGTON, Aug. 20 /PRNewswire/ -- A poll released today by the Family Research Council reveals most Americans -- 62 percent -- oppose needle exchange programs (NEPs) and 60 percent favor drug abstinence and drug rehabilitation programs as a more effective way to stop the spread of AIDS/HIV. Fifty-six percent believe
- FRC Asks: Are Taxpayers Ready to Subsidize Heroin Addicts? FRC to Introduce National Poll on Needle Exchange Programs
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday August 13, 1997 - 7:02 AM EDT
- Donna Shalala is feeling the heat. The American Medical Association , the National Institutes of Health, the U.S. Conference on Mayors, and others are strongly urging her to lift the ban on federally funded needle exchange programs (NEPs). Last month, the Washington Post said that study after study shows that the exch
- Pediatric AIDS Foundation Endorses Proposed Mandate Requiring Drug Manufacturers to Perform Pediatric Studies on New Drugs; Proposed FDA Regulation Guarantees Children Access to Safe and Effective Drugs
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday August 13, 1997 - 3:22 PM EDT
- WASHINGTON, Aug. 13 /PRNewswire/ -- President Clinton, First Lady Hillary Rodham Clinton, and Vice President Al Gore announced today a proposed Food and Drug Administration regulation requiring drug manufacturers to perform Pediatric studies for new drugs that will be used by children. Currently, 80% of the drugs marke
- The Philadelphia AIDS Consortium: HIV System Advocates for Improved Medical Care for People Living With HIV/AIDS
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday August 13, 1997 - 5:50 PM EDT
- PHILADELPHIA, Aug. 13 /PRNewswire/ -- On August 11, 1997, Larry Hochendoner, Executive Director of the Philadelphia AIDS Consortium, presented his testimony before the House Health and Human Services Committee at a hearing that focused on special needs populations and managed care. The purpose of the testimony was to f
- Saliva Diagnostics Announces Increased Shelf Life for Its Rapid HIV Tests
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 11 August 1997, 6:00 a.m. EDT
- VANCOUVER, Wash., Aug. 11 /PRNewswire/ -- Following a number of stability studies, Saliva Diagnostic Systems (Nasdaq:SALV), Inc. ( SDS ) has upgraded the shelf life of its rapid HIV tests from 12 to 18 months, increasing by six months the length of time from date of manufacture that the tests can be stored at room temp
- MARINOL(R) (dronabinol) Fact Sheet
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday, 8 August 1997.
- COLUMBUS, Ohio, Aug. 8 /PRNewswire/ -- Roxane Laboratories issues the following fact sheets about MARINOL: Brand Name: MARINOL(R) Generic Name: dronabinol Chemical Name: Delta-9-tetrahydrocannabinol or delta-9-THC. Indication MARINOL is approved for the following indications: 1. For nausea and vomitting associated
- Abbott Northwestern Hospital's Clinic 42 Participates in New HIV Drug Trial
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday August 7, 1997 - 5:22 PM EDT
- MINNEAPOLIS, Aug. 7 /PRNewswire/ -- Abbott Northwestern Hospital s Clinic 42 will be conducting two clinical trials of a new drug for people with human immunodeficiency virus (HIV). Clinic 42 will be the only Minnesota site for these trials. The studies involve an experimental antiretroviral drug -- 1592U89 -- which ha
- Foundation Planning Group: Financial Assistance for Terminally Ill People
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - May 1997.
- BELLEVUE, Wash., Aug. 6 /PRNewswire/ -- People suffering with a terminal illness and in need of financial help may sell their life insurance policies to viatical funding companies at a discount to their face value. In some cases the cash received is free from federal income taxes. Viatical funding companies raise money
- Saliva Diagnostic's Rapid HIV Test Scores High Rating in Independent Study
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 6 August 1997
- VANCOUVER, Wash., Aug. 6 /PRNewswire/ -- A rapid HIV test developed by Saliva Diagnostic Systems, Inc. (Nasdaq:SALV) rated high in overall performance, according to an independent study recently completed by scientific investigators(1). The study evaluated the ability of six serum immunoassays to detect HIV antibodies
- Open Label Access to Investigational Anti-HIV Compound 1529U89 Begins; Expanded Access Program to Begin in 1998
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 6 August 1997.
- RESEARCH TRIANGLE PARK, N.C., Aug. 6 /PRNewswire/ -- A worldwide open label clinical trial of the investigational anti- HIV drug known as 1592 has begun and is expected to enroll up to 2,400 qualified adult AIDS patients in the United States by year s end. Based on safety data collected in this open label trial, as wel
- FDA Clears TAXOL for AIDS-Related Kaposi's Sarcoma
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 5 August 1997
- PRINCETON, N.J., Aug. 5 /PRNewswire/ -- Bristol-Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration has cleared TAXOL(R) (paclitaxel) Injection for use in second-line treatment of AIDS- related Kaposi s sarcoma (KS). Bristol-Myers Squibb (BMS) pioneered the commercial development of TAXO
- IVAX Announces FDA Advisory Panel to Review Paxene(R) for Kaposi's Sarcoma
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 5 August 1997.
- MIAMI, Aug. 5 /PRNewswire/ -- IVAX Corporation (Amex: IVX) today announced that it has been invited to present clinical data regarding Paxene(R) for Kaposi s sarcoma to the FDA s Oncology Drugs Advisory Committee (ODAC) on the morning of September 19, 1997. Earlier this year, IVAX and NaPro BioTherapeutics, Inc. (Nasda
- Russia Approves AmBisome and DaunoXome
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 4 August 1997.
- BOULDER, Colo., Aug. 4 /PRNewswire/ -- NeXstar Pharmaceuticals, Inc. (Nasdaq: NXTR) today announced that the Russian Ministry of Health granted marketing approval for its two proprietary liposomal products, AmBisome and DaunoXome. The Russian Ministry of Health approved AmBisome, the company s liposomal antifungal drug
- Barr Information on Warfarin Usage Could Harm Patients, Dupont Merck Says
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday August 1, 1997 - 2:13 PM EDT
- WILMINGTON, Del., Aug. 1 /PRNewswire/ -- The DuPont Merck Pharmaceutical Company said today that educational and prescribing materials circulated by Barr Laboratories (Amex:BRL) in its launch of a generic warfarin contain serious errors that could pose a potential danger to patients and should be recalled. DuPont
- National Association Of People With AIDS: News of AZT Structural Flaw Highlights; Need for Broad Awareness of HIV Treatment Options
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday July 31, 1997 - 12:27 PM EDT
- WASHINGTON, July 31 /PRNewswire/ -- Reports of new research published in the August issues of Nature Medicine and Nature Structural Biology raise questions for people with HIV disease who are considering their treatment options. The research suggests that AZT , an agent in the class of drugs called thymidine analogs
- CEL-SCI Corporation Announces Issuance of U.S. Patent on Promising Immune System Technology
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday July 29, 1997 - 8:29 AM EDT
- ALEXANDRIA, Va., July 29 /PRNewswire/ -- CEL-SCI CORPORATION (AMEX:HIV) announces the issuance of a U.S. Patent on CEL-SCI Corporation s L.E.A.P.S.(TM) heteroconjugate technology. The patent, number 5,652,342, was filed in 1988 and is titled Heterofunctional Cellular Immunological Reagents, vaccines containing same and
- SmithKline Beecham Files With the FDA for the Use of Famvir(R) in Immunocompromised Patients; Studies Show Famvir Safe and Effective for Immunocompromised Patients
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday July 29, 1997 9:59 AM EDT
- PHILADELPHIA, July 29 /PRNewswire/ -- SmithKline Beecham (NYSE:SBH) announced today that it has filed a supplemental new drug application with the U.S. Food and Drug Administration for the use of Famvir(R) (famciclovir) in the treatment of herpes simplex virus (HSV) infections and acute herpes zoster (shingles) infecti
- Hybridon Stops Development of Gem(R)91 for AIDS; Resources to be Focused on Four 2nd Generation Compounds
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday, 25 July 1997.
- CAMBRIDGE, Mass., July 25 /PRNewswire/ -- Hybridon Inc. (Nasdaq: HYBN) today announced that it has elected to stop further development of its first generation antisense drug, GEM(R)91, based on a preliminary review of new data from an open label Phase II clinical trial of patients with advanced HIV infection. GEM91 is
- DynaGen, Inc. Announces ImmuDyne, Its Immune Modulation Drug Development Program
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 16 July 1997.
- CAMBRIDGE, Mass., July 16 /PRNewswire/ -- DynaGen, Inc. (Nasdaq: DYGN; BSE: DYG) today announced that it has decided to expand its ImmuDyn(TM) drug development program. ImmuDyn is a proprietary lipid preparation that modulates immune system function. Immune modulators have shown potential clinical usefulness as either
- Agouron and JT Grant Roche Marketing Rights in Asia
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - May 1997.
- LA JOLLA, Calif., July 15 /PRNewswire/ -- It was announced today that Agouron Pharmaceuticals, Inc. (Nasdaq-NNM: AGPH) and Japan Tobacco Inc. (JT) have granted F. Hoffmann-La Roche Ltd. (Roche) exclusive marketing rights for the anti- HIV drug VIRACEPT(R) (nelfinavir mesylate)* in several Asian territori
- Isis and CIBA Vision Establish Agreement For Worldwide Distribution of Novel CMV Retinitis Drug
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday July 15, 1997 - 5:44 AM EDT
- CARLSBAD, Calif. and BUELACH, Switzerland , July 15 /PRNewswire/ -- Isis Pharmaceuticals , Inc. (Nasdaq:ISIP) and CIBA Vision Corporation (a Novartis company) announced today an agreement granting CIBA Vision exclusive worldwide distribution rights for fomivirsen (ISIS 2922), an antisense drug to treat AIDS-related
- Pediatric Aids -- The New Face Of HIV See for Yourself...on The Cutting Edge Medical Report
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday July 14, 1997 - 2:53 PM EDT
- BOCA RATON, Fla., July 14 /PRNewswire/ -- The first cases of children with HIV infection were described in 1983. Since that time, 1.3 million children worldwide have died as a result of complications from AIDS. And while the present figures are staggering, recent advances in medical technology offer hope for the future
- Novavax Receives FDA Permission To Begin Dose-Response Studies With ANDROSORB(TM)
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 14 July 1997
- COLUMBIA, Md., July 14 /PRNewswire/ -- Novavax, Inc. (AMEX: NOX) today announced that it has been allowed by the FDA to proceed with pharmacokinetic- dose response studies of ANDROSORB(TM), a proprietary topical micellar nanoparticle (MNP) cream containing testosterone, in testosterone-deficient males. ANDROSORB is
- Philadelphia AIDS Consortium Eliminates All Conflict of Interest: Embraces Consumer Board
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday July 11, 1997 - 12:13 PM EDT
- PHILADELPHIA, July 11 /PRNewswire/ -- In a precedent setting meeting of the Board of Directors of the Philadelphia AIDS Consortium, an agreement was reached with the Commonwealth of Pennsylvania that all conflict of interest or perception of conflict of interest would be eliminated from the Board of Directors. Accordin
- Statement from the American Academy of Periodontology on the Center for Disease Control (CDC) Report Linking Gum Disease to HIV Transmission
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday July 11, 1997 6:45 PM EDT
- CHICAGO, July 11 /PRNewswire/ -- The American Academy of Periodontology (AAP) today released the following: The American Academy of Periodontology (AAP) is deeply concerned about the possible role gum diseases could play in the transmission of the HIV virus from infected individuals to their uninfected partners. Acco
- IRD Questions NCC Endorsement of Planned Parenthood Sex Ed Video
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 10 July 1997.
- WASHINGTON, July 10 /PRNewswire/ -- A new Planned Parenthood sex education video kit carries the endorsement of a National Council of Churches official responsible for Christian education. Although the video kit defends abortion as safe and suggests that homosexual relationships can be fulfilling, the NCC official stat
- Vertex and Glaxo Wellcome Announce Pivotal Phase III Trial of HIV Protease Inhibitor 141W94 (VX-478) in Pediatric Patients
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday July 10, 1997 - 9:34 AM EDT
- CAMBRIDGE, Mass., July 10 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) announced today that its partner, Glaxo Wellcome plc (NYSE:GLX), has begun a pivotal Phase III clinical trial to evaluate the safety and efficacy of 141W94 (VX-478) in combination with nucleoside reverse transcriptase inhibitor
- We The People Living with AIDS/HIV: African American People with AIDS Protest City Shift of AIDS Funds - `Takeover' by Sen. Hardy Williams Charged; Protest Set
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 9 July 1997.
- PHILADELPHIA, July 9 /PRNewswire/ -- African American people living with AIDS are joining with black community advocates and AIDS service providers to organize against a city health department pledge to give $200,000 to an ad hoc group set up by State Sen. Hardy Williams (D-West Philadelphia). The group plans a demonst
- CEL-SCI Corporation Announces Development of a Potential AIDS Vaccine For Worldwide Use
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 9 July 1997.
- ALEXANDRIA, Va., July 9 /PRNewswire/ -- CEL-SCI CORPORATION (AMEX: HIV ) announces the development of an improved version of its HGP-30 AIDS vaccine. The new modified version is called HGP-30W, where W stands for worldwide. It is hoped that HGP-30W will provide better worldwide protection against a large number of HIV
- ALRT Announces Oral Panretin Clinical Trials Update - AIDS Malignancy Consortium Advances KS Trial
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 8 July 1997.
- SAN DIEGO, July 8 /PRNewswire/ -- Allergan Ligand Retinoid Therapeutics, Inc. (ALRT) (Nasdaq: ALRI) announced today an update on the status of clinical trials with one of its lead products, Panretin(TM) (9-cis-retinoic acid) Oral capsules. In the areas of Kaposi s sarcoma (KS), psoriasis and myelodysplastic syndrome (M
- PUR Unveils Undersink Water Filter For Hardware and Home Center Class of Trade
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 3 July 1997.
- MINNEAPOLIS, July 3 /PRNewswire/ -- PUR, the technology leader in water filters, will begin shipping its newest product in the PUR Family -- The US-7000 Undersink Water Filter -- in July. This new undersink water filter was developed specifically for the Hardware and Home Center Class of trade. The US-7000 was designed
- ArQule, Inc. Announces Collaboration with the University of California San Francisco for Discovery and Development of Viral Protease Inhibitors
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday July 2, 1997 - 12:10 PM EDT
- MEDFORD, Mass., July 2 /PRNewswire/ -- ArQule, Inc. (Nasdaq:ARQL) today announced that it has entered into a sponsored research agreement with the University of California San Francisco (UCSF) for the discovery and design of novel protease inhibitors . Under terms of the agreement, ArQule will assess and select compoun
- Protein Design Labs Announces Results From Phase II Study of PROTOVIR(TM) in Bone Marrow Transplantation
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 1 July 1997.
- MOUNTAIN VIEW, Calif., July 1 /PRNewswire/ -- Protein Design Labs, Inc., (PDL) (Nasdaq: PDLI) announced today results of a Phase II clinical trial of its PROTOVIR (sevirumab) human anti- cytomegalovirus ( CMV ) antibody for the prevention of CMV infections in allogeneic (donor) bone marrow transplantation.
- CONFIDE HIV Service Withdrawn from Market
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday June 26, 1997 - 2:31 PM EDT
- BRIDGEWATER, N.J., June 26 /PRNewswire/ -- Direct Access Diagnostics today announced that its CONFIDE HIV Testing and Counseling Service is being withdrawn from the market, effective immediately, due to lack of consumer demand. After a year on the market, the usage level of CONFIDE is quite low, said Robert B. Miller,
- New Oral HIV Test Available Free at Anonymous Test Sites Easy, Painless Test Involves No Needles
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday June 26, 1997 - 6:06 PM EDT
- PHILADELPHIA, June 26 /PRNewswire/ -- In recognition of National HIV Testing Day, the Philadelphia AIDS Consortium (TPAC) and SmithKline Beecham are teaming up to distribute a new oral HIV test that is quick, easy and totally noninvasive. A thousand of the new tests, called OraSure will be available, free of charge, at
- NIAID Commences Clinical Trial with Therion Biologics' Recombinant Multi-antigen AIDS Vaccine, TBC-3B
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 25 June 1997.
- CAMBRIDGE, Mass., June 25 /PRNewswire/ -- Therion Biologics Corporation announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has initiated a second Phase I clinical trial with TBC-3B, Therion s recombinant vaccine for the prevention of AIDS. The trial is the first study to evaluate TBC
- CORRECTION -- Pharmacia & Upjohn: New AIDS Drug Arriving at Pharmacies
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - May 1997.
- In New AIDS Drug Arriving at Pharmacies, moved earlier today, we are advised by a representative of the company of numerous revisions in the original release. Following is the corrected release: KALAMAZOO, Mich., June 25 /PRNewswire/ -- Shipments of Rescriptor Tablets (
- Oncology Drugs Advisory Committee Recommends TAXOL(R) for Kaposi's Sarcoma
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 23 June 1997.
- PRINCETON, N.J., June 23 /PRNewswire/ -- The Oncology Drugs Advisory Committee (ODAC) today recommended that the U.S. Food and Drug Administration approve TAXOL for the treatment of Kaposi s Sarcoma (KS). As a research-based company, and a leader in the fight against AIDS, Bristol-Myers Squibb is extremely pleased
- Pure H20 Bio-Technologies Cleared For Trading; Reports 100% `Kill' On Cryptosporidium with Purification/Disinfection
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 23 June 1997.
- BOYNTON BEACH, Fla., June 23 /PRNewswire/ -- Pure H20 Bio-Technologies has been cleared for trading on the Over The Counter (OTC) Bulletin Board, symbol, PHBT. The company also reported that its water disinfection/purification systems killed cryptosporidium , a deadly water-borne disease that has already killed more th
- International Organizations Call for HIV Vaccine Development
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Sunday, 22 June 1997.
- DENVER, June 22 /PRNewswire/ -- More than fifty of the world s leading AIDS-related non-governmental organizations joined today in urging representatives at the Denver Summit of Eight here to accept the challenge from the President of the United States to act in concert to develop vaccines to stop the global AIDS epide
- Largest-Ever AIDS Study Finds Three Drug AIDS Cocktail Better Than Two
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 20 June 1997.
- THIS PRESS RELEASE IS A REVISED VERSION OF A RELEASE DISTRIBUTED ON FRIDAY, June 20. Please Refer to This Version if You are Developing Any AIDS Stories. NUTLEY, N.J., June 20 /PRNewswire/ -- New data from the largest-ever AIDS study shows that using a three drug cocktail -- the protease inhibitor INVIRASE(R) (saquinav
- AIDS-Related Virus Linked to Common Bone Marrow Cancer; Discovery Could Lead to New Treatments for Myeloma
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 19 June 1997.
- LOS ANGELES, June 19 /PRNewswire/ -- Reporting in the June 20 issue of the journal Science, researchers with the U.S. Department of Veterans Affairs (VA) have identified a surprising culprit -- an AIDS-associated virus -- which could play a critical role in triggering multiple myeloma, a malignant tumor found in bone m
- Sarawak MediChem Pharmaceuticals Begins Clinical Trial of Anti-HIV Agent Calanolide A
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, June 18, 1997 11:04 AM EDT
- LEMONT, Ill., June 18 /PRNewswire/ -- Sarawak MediChem Pharmaceuticals, Inc., has begun screening patients for a 50-patient Phase IA clinical trial of (+)-Calanolide A, an anti-HIV agent discovered by the National Cancer Institute in the rain forest of Sarawak, Malaysia . The single-center, seven- month trial will be p
- Comprehensive Reports From Premier HIV/Aids Clinical Meeting Now Available on World Wide Web; Highlights of 7th Annual 'Clinical Care Options For HIV Symposium' Available At http://www.healthcg.com
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, June 18, 1997 7:55 AM EDT
- POTOMAC, Md., June 18 /PRNewswire/ -- Comprehensive reports and syllabus materials from the 7th Annual Clinical Care Options for HIV Symposium are now available on the world wide web at http://www.healthcg.com, featured as a part of the full text online publication Clinical Care Options for HIV(SM) Journal. These detai
- Mexican Ministry of Health Recommends New Digene HIV Viral Load Test for Aids
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday 17 June 1997.
- BELTSVILLE, Md., June 17 /PRNewswire/ -- Digene Corporation (Nasdaq: DIGE) announced today that the Ministry of Health of the Republic of Mexico has recommended that the Digene HIV RNA test be used for the monitoring of AIDS patients by all reference laboratories in Mexico. The decision was based on an extensive evalua
- Incyte Completes First Phase Sequencing of Candida Albicans Genome
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 16 June 1997.
- PALO ALTO, Calif., June 16 /PRNewswire/ -- Incyte Pharmaceuticals, Inc. (Nasdaq: INCY) announced today that it has completed the initial phase of sequencing Candida albicans, the first pathogenic fungal genome in Incyte s microbial genomics program. Incyte scientists have completed sequencing one fold coverage of a vir
- Viral Load and CD4 Counts Offer Best Prognostic Tools
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Saturday 14 June 1997.
- BALTIMORE, June 14 /PRNewswire/ -- A combination of measuring plasma viral load (the amount of genetic material in circulating virus) and CD4 + lymphocytes in people who are HIV -infected gives the most accurate prediction of the time when those people will develop AIDS. This information forms a critical part of the de
- Multicenter AIDS Cohort Study Improves Prognostic Tools for AIDS and HIV-Infected Patients
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday June 13 4:31 PM EDT
- FOR RELEASE AT 5 P.M., EDT SATURDAY, JUNE 14/ /ADVANCE/PITTSBURGH, June 14 /PRNewswire/ -- The development of effective treatments for some AIDS patients within the past few years has presented physicians with the new dilemma of when to initiate therapy. A report in the June 15 issue of Annals of Internal Medicine show
- Standard Insurance Company Introduces an Unprecedented Accelerated Benefit Provision With a Beneficiary Payout
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 11 June 1997.
- PORTLAND, Ore., June 11 /PRNewswire/ -- Standard Insurance Company has broken new ground by ensuring that its terminally ill insureds can get greater benefit from their group term life insurance coverages while living, and seeing to it that funds also remain for their beneficiaries. In a series of enhancements to its A
- CEL-SCI CORPORATION Announces Permission to Start Cancer Study in Canada
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 10 June 1997.
- ALEXANDRIA, Va., June 10 /PRNewswire/ -- CEL-SCI CORPORATION (AMEX: HIV ) announced today that the Canadian Health Protection Branch (HPB) has given permission to start a clinical trial with CEL-SCI s immunotherapy drug Multikine(TM). The study will enroll 14 patients having squamous cell carcinoma of the head and neck
- USF Researcher: Study Of Cannabinoid Receptor System Shows Marijuana Alters Immunity As Well As Mood
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 9 June 1997
- TAMPA, Fla., June 9 /PRNewswire/ -- In Dr. Thomas Klein s crowded laboratory office, beneath the shelves of scientific journals hangs a preserved puffer fish with an imitation joint dangling from its mouth. Even the ancient blowfish has been found to harbor chemical receptors that react to delta-9 tetrahydrocannabinol,
- LXR Biotechnology Inc. Reassesses Strategy of Lexirin(TM) U.S. Clinical Development in Light of Recent Success of AIDS Triple Therapy
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday June 5 8:25 AM EDT
- RICHMOND, Calif., June 5 /PRNewswire/ -- LXR Biotechnology (AMEX:LXR), today announced a change in the strategy of clinical development of Lexirin(TM), one of its lead investigational drugs. In recent preclinical trials, results have lent further support that Lexirin protects cells in the intestinal lining of an animal
- Incenter Publishes a Comprehensive Analysis of The Worldwide HIV/Aids Therapeutic Market; Report Analyzes the Clinical, Financial, and Regulatory Issues Impacting the Market
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday June 4 8:26 AM EDT
- WASHINGTON, June 4 /PRNewswire/ -- Incenter Strategies, Inc., a Washington, D.C.-based health care information consulting firm, announces the publication of HIV/AIDS Therapeutic Market Report, a comprehensive review of the HIV/AIDS therapeutic market, including analyses of the clinical, financial, and regulatory outloo
- Clinical Study Examines Nutrient Mixture's Ability to Prevent Muscle Wasting in AIDS Patients
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday June 3 12:27 PM EDT.
- AMES, Iowa, June 3 /PRNewswire/ -- Researchers are giving HIV-positive patients a new nutrient mixture that combines the leucine metabolite HMB with certain amino acids as part of a clinical study to determine if the mixture will help slow the muscle wasting that AIDS patients experience. Our objective is to determine
- ChemTrak(R) Reports New Aware(TM) Rapid HIV Test Meets ELISA/Western Blot Accuracy in Pre-Clinical Trials
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday June 3 3:39 PM EDT.
- SAN FRANCISCO, June 3 /PRNewswire/ -- ChemTrak, Inc. (Nasdaq:CMTR) today reported it has successfully completed pre-clinical trials of the one-step AWARE Rapid HIV Test (Rapid HIV Test) with results equivalent to the gold standard Western Blot and ELISA testing methods. The significant differentiating factor: Rapid HIV
- AIDS ReSEARCH ALLIANCE and CEL-SCI Corporation Announce Start of HIV Study with Multikine(TM)
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday June 3 8:29 AM EDT
- ALEXANDRIA, Va., June 3 /PRNewswire/ -- AIDS ReSEARCH ALLIANCE AND CEL-SCI CORPORATION (Nasdaq:CELI) jointly announce the start of a HIV treatment study with CEL-SCI s immunotherapy drug, Multikine. The study will involve 14 healthy HIV positive patients. The purpose of the study is to evaluate the safety of Multikine
- Bristol-Myers Squibb Acquires New HIV Protease Inhibitors from Novartis
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 3 June 1997.
- PRINCETON, N.J., June 3 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE:BMY) said today it has acquired worldwide development and marketing rights from Novartis Pharma AG for two protease inhibitor compounds under investigation for the treatment of HIV/AIDS. Under the terms reached by the two companies, Bristol-Myer
- BioSource International Releases Quantitative Test Kit for Cytomegalovirus; Accurate Measurement of CMV Viral Load Now Available to Drug Development Firms and Clinical Researchers
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 2 June 1997.
- CAMARILLO, Calif., June 2 /PRNewswire/ -- BioSource International, Inc. (Nasdaq: BIOI) today announced the market release of a quantitative assay for gene amplification of cytomegalovirus ( CMV ). ViralQuant- CMV is the first commercially available assay for accurate measurement of gene-amplified samples of CMV to dete
- Revolutionary HIV Drug Resistance Test Launched Worldwide By International Murex; Breakthrough Test Provides Physicians Invaluable Information About When The HIV Virus Is Mutating and Drug Resistance Occurs
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday May 29, 1997 - 10:04 AM EDT
- TORONTO, May 29 /PRNewswire/ -- A breakthrough in the treatment of patients with HIV and AIDS was launched worldwide today by International Murex Technologies Corporation (Nasdaq:MURXF - news) and Innogenetics NV. The Companies revolutionary LiPA(TM) HIV-1 Reverse Transcriptase (RT) test is the first-ever commercially
- Sheffield Announces Issuance of Patent and Clinical Results for its RBC-CD4 Program; To Look for Partner Committed to HIV /AIDS Market
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 29 May 1997.
- NEW YORK, May 29 /PRNewswire/ -- Sheffield Medical Technologies Inc. (AMEX: SHM) announced today that it has received a Notice of Allowance from the United States Patent Office for its application covering insertion of recombinant human CD4 protein into mammalian-derived red blood cells. Allowed claims also cover incor
- Saliva Diagnostic Systems Announces Sales and Distribution Agreement With APS Canada
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 28 May 1997.
- VANCOUVER, Wash., May 28 /PRNewswire/ -- Saliva Diagnostic Systems, Inc. (Nasdaq: SALV) announced today it has signed a sales and distribution agreement with APS Canada to sell SDS rapid diagnostic tests and patented test components in Canada and selected countries worldwide especially in the Middle East and parts of A
- Investigational Antiretroviral Therapy Achieves Undetectable HIV Levels; Given Once a Day in Combination with Crixivan, DMP 266 Eliminates Measurable HIV in 80 Percent of Patients
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 27 May 1997.
- LAUSANNE, Switzerland , May 27 /PRNewswire/ -- Forty-two week data from an initial, ongoing phase II study of DuPont Merck s DMP 266 in combination with Crixivan (R) ( indinavir ) found 80 percent of patients achieved HIV -RNA below level of quantification
- Study Shows Famvir(R) is a Safe and Effective Treatment for Herpes in HIV-Infected Patients
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 27 May 1997.
- OTTAWA, May 27 /PRNewswire/ -- Famvir(R) (famciclovir, SmithKline Beecham) is a safe and effective treatment for herpes simplex virus infections in HIV - infected patients, according to a new study presented at the Canadian Conference on HIV / AIDS Research in Ottawa. The study showed that a twice daily dose of Famvir
- Playboy Playmate Rebekka Armstrong Speaks Out About Living With AIDS
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday May 23, 1997 12:02 PM EDT
- NEW YORK, May 23 /PRNewswire/ -- Playboy s September 1986 Playmate Rebekka Armstrong, who was diagnosed as HIV-positive in 1989, will be a featured speaker at the 1997 POZ Life Expo at Jacob Javits Center on May 30-31 from 10:00 a.m. to 6:00 p.m. Thirty-year-old Rebekka has been an active spokesperson and educator on A
- Thalidomide Effectively Heals Aphthous Ulcers in AIDS Patients, NIH Study Shows
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday May 22, 1997 5:42 PM EDT
- BELTSVILLE, Md., May 22 /PRNewswire/ -- In the first nationwide controlled clinical trial to provide evidence of the effectiveness of the drug thalidomide against a serious illness, a study published in today s issue of The New England Journal of Medicine reported that 90% of HIV-positive patients with aphthous ulcers
- Nabi Acquires Autoplex(R) T from Baxter Healthcare Corporation
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 21 May 1997.
- BOCA RATON, Fla., May 21 /PRNewswire/ -- Nabi (Nasdaq: NABI) today announced that it has acquired the exclusive rights in the United States Canada and Mexico to Autoplex T, an anti-inhibitor hemophilia treatment from Baxter Healthcare Corporation. Under the terms of the agreement, Baxter will continue to manuf
- SunPharm Corporation Reports in 'The Journal of Organic Chemistry' the Ability to Synthesize Novel Hypusine Reagent: Potential Application for Treating HIV , Using a Cellular Target
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - May 1997.
- JACKSONVILLE, Fla., May 19 /PRNewswire/ -- SunPharm Corporation (Nasdaq: SUNP) today announced the publication of a scientific paper in the May 16 issue of The Journal of Organic Chemistry that describes the synthesis of a peptide containing an unusual amino acid called hypusine. Hypusine is normally found in a protein
- National Consumer Advocate Organization Says Clinton Administration is Playing Politics With the AIDS Vaccine
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 19 May 1997.
- WASHINGTON, May 19 /PRNewswire/ -- Citing the dangers of mixing politics with science, the National Vaccine Information Center (NVIC) says the Clinton Administration is playing politics by issuing a national call to rush an AIDS vaccine to the market within 10 years. The 15-year old consumer advocate organization point
- President Clinton's National Goal of Finding an AIDS Vaccine Strongly Endorsed by CEL-SCI Corporation
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - May 1997.
- ALEXANDRIA, Va., May 19 /PRNewswire/ -- At a commencement address at Morgan State University, on Sunday, May 18, 1997, President Clinton set a national goal of finding a vaccine to prevent AIDS within 10 years. The President compared the search for an AIDS vaccine to John F. Kennedy s challenge 36 years ago to put a ma
- Michigan Teens Will Learn AIDS Prevention Skills At Midwest AIDS Prevention Project Youth Conference on Monday, May 19
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 19 May 1997.
- FERNDALE, Mich., May 19 /PRNewswire/ -- More than 300 teens from across the state are expected to attend a Michigan AIDS conference for young HIV educators on Monday, May 19 at the University of Detroit Mercy Ward Conference Center in Detroit from 9 a.m. to 3:30 p.m. Called Living, Loving, Learning -- United We Stand,
- Famvir, from SmithKline Beecham, Approved in the UK for Suppression Of Recurrent Genital Herpes
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday 16 May 1997.
- LONDON, May 16 /PRNewswire/ -- SmithKline Beecham (NYSE: SBH) (SB) announced today that its antiviral medicine Famvir (famciclovir) has been approved for use in the suppression of genital herpes (herpes simplex) in the United Kingdom . This is the first market to launch Famvir for this condition anywhere in the world.
- Dr. David Ho, World-Renowned HIV/AIDS Researcher and Time Magazine's '1996 Man Of The Year' to Serve as Senior HIV/AIDS
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - May 1997.
- LOS ANGELES, May 15 /PRNewswire/ -- Dr. David Ho, world-renowned HIV /AIDS researcher, and Time magazine s 1996 Man Of The Year, will be senior consultant for the BENTLEY HEALTH CARE, Inc. HIV /AIDS division. Dr. Ho has been internationally recognized for his groundbreaking work with protease inhibitors
- FDA Approves Clinical Studies With ANTICORT
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 15May 1997.
- LAS VEGAS, May 15 /PRNewswire/ -- Steroidogenesis Inhibitors, Inc. (SII) announced today that it will start a Phase Ib/IIa clinical trial program with its lead product ANTICORT after receiving clearance from the Division of Anti- Viral Products of the FDA . This clearance follows the submission of an Investigational Ne
- Yes, Mr. Clinton, Apologize to Victims of the Tuskegee 'Experiment,' But What About the Baby Victims of the CDC AIDS
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 15May 1997.
- WASHINGTON, May 15 /PRNewswire/ -- The Independent Women s Forum (IWF) today called upon President Clinton to apologize to the thousands of American babies denied treatment for HIV by the Centers for Disease Control at the same time that he apologizes for the Tuskegee Experiment, in which 399 black men were denied trea
- ARVO Presentations Show Safety and Efficacy of Isis' CMV Retinitis Drug; Patients who have failed all other therapies including cidofovir experience prolonged response and lower retinal detachment rate with fomivirsen (ISIS 2922)
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 15May 1997.
- CARLSBAD, Calif., May 15 /PRNewswire/ -- Clinical investigators of Isis Pharmaceuticals (Nasdaq: ISIP) antisense drug for CMV retinitis today presented data at the Association for Vision Research and Ophthalmology (ARVO) meeting in Ft. Lauderdale, Florida, showing that fomivirsen (ISIS 2922), an antisense inhibitor of
- The Liposome Company Granted Approval for ABELCET(R) in Switzerland
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 15May 1997.
- PRINCETON, N.J., May 15 /PRNewswire/ -- The Liposome Company, Inc. (Nasdaq: LIPO) has received approval for ABELCET(R) (Amphotericin B Lipid Complex Injection) in Switzerland . The indicated uses for ABELCET are for the first-line treatment of candidiasis and for the treatment of severe systemic fungal infections in p
- Merck Crixivan: Full prescribing information for Crixivan follows: CRIXIVAN(R) (INDINAVIR SULFATE) CAPSULES
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 14 May 1997.
- WARNING CRIXIVAN is indicated for the treatment of HIV infection in adults when antiretroviral therapy is warranted. This indication is based on analyses of surrogate endpoints in studies of up to 24 weeks in duration. At present, there are no results from controlled clinical trials evaluating the effect of therapy wit
- Merck's Crixivan(R) Now Available From Many Pharmacies
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 14 May 1997.
- WEST POINT, Pa., May 14 /PRNewswire/ -- Crixivan ( indinavir sulfate), the anti-HIV protease inhibitor most often prescribed by doctors(1), is now available at participating local pharmacies nationwide, increasing access to this potent therapy for people with HIV /AIDS.
- Life Threatening CMV Disease May Be Prevented in Kidney Transplant Recipients with Oral Cytovene(R)
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 13 May 1997.
- CHICAGO, May 13 /PRNewswire/ -- Data presented this weekend at the annual meeting of the American Society of Transplant Physicians confirm that oral ganciclovir (Cytovene(R) capsules) may prevent potentially life-threatening cytomegalovirus ( CMV ) infection and disease in renal transplant recipients.
- Roche Submits New Drug Application for New Formulation of HIV Protease Inhibitor; Provides Eight to Nine Times the Exposure of Current Formulation At Studied Dose
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 12 May 1997.
- NUTLEY, N.J., May 12 /PRNewswire/ -- Hoffmann-La Roche Inc. announced today that it has submitted a New Drug Application (NDA) to the Food and Drug Administration for a new formulation of its HIV protease inhibitor saquinavir mesylate. At the dose used in clinical trials , the new formulation, a soft gelatin capsule, p
- Apothecus' Contraceptive Film First Spermicide Shown Safe in Regard to HIV Transmission
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 12 May 1997.
- OYSTER BAY, N.Y., May 12 /PRNewswire/ -- Dr. Louise Tyrer, Medical Director of the Association of Reproductive Health Professionals announced today that a recently concluded multimillion dollar government-sponsored study showed that the use of N-9 Film, did not increase the risk of HIV or STD transmission. According to
- Bristol-Myers Squibb Company Announces Nationwide Availability of VAGISTAT-1; First One-Dose OTC Vaginal Yeast Infection
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 12 May 1997.
- NEW YORK, May 12 /PRNewswire/ -- VAGISTAT(R)-1 (tioconazole 6.5%) vaginal ointment, the first and only one-dose, over-the-counter (OTC) medication for vaginal yeast infections, is now available in drug and food stores as well as mass merchandise outlets nationwide. One-Dose Convenience and Patient Compliance VAGIST
- The Immune Response Corporation Completes Enrollment of 2,500 Patient Phase III Clinical Trial of REMUNE(TM)
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 12 May 1997.
- CARLSBAD, Calif., May 12 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that it has completed enrollment of its nationwide Phase III clinical trial of REMUNE, a therapy that fights HIV by stimulating the patient s own natural defense mechanisms against the virus. This is the largest tria
- LIDAK Pharmaceuticals Reports Additional Data From Kaposps Sarcoma Trial At International Conference
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 9 May 1997.
- LA JOLLA, Calif., May 9 /PRNewswire/ -- Today at The Second International Conference on Human Herpes Viruses 6, 7, and 8 in Pisa, Italy , LIDAK Pharmaceuticals (Nasdaq NNM: LDAKA) reported additional data from its clinical trials with the topical formulation of its proprietary drug, n-docosanol (LIDAKOL(R)) in the trea
- Durex Sheik Survey Shows Condoms Less Likely, High Risk Behavior More Common at Spring Break
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 8 May 1997.
- ATLANTA, May 8 /PRNewswire/ -- According to a Durex Sheik online survey of visitors to Panama City Beach during last month s spring break, college students are actually less sexually active during spring break than they are back on campus, despite long-standing perceptions to the contrary. That s the good news. The bad
- Demeter Announces Its Peptidyl MIMs(TM) Kill Multi-Drug-Resistant Bacteria
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - March 1997.
- DURHAM, N.C., May 8 /PRNewswire/ -- Demeter BioTechnologies, Ltd. (OTC-DBOT) announced that select Peptidyl Membrane Interactive Molecules (Peptidyl MIMs(TM)) were effective in vitro in killing a number of microorganisms which demonstrate resistance to current antibiotics. The results were presented by Demeter at the A
- Epoch Demonstrates Site-Directed Gene Modification in Living Cells
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 8 May 1997.
- BOTHELL, Wash., May 8 /PRNewswire/ -- Epoch Pharmaceuticals, Inc. (OTC Bulletin Board: EPPH) announced today that their Gene Modifying Oligonucleotide technology has been successfully applied to living cells. The Company believes that this demonstration of highly specific targeted modification of a gene is the first re
- Anvirzel(TM): a New Weapon Against Cancer and AIDS
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 8 May 1997.
- COSTA MESA, Calif., May 8 /PRNewswire/ -- Steve Solsbery of Texas-based Ozelle Pharmaceuticals says that his company has developed a new weapon against cancer and AIDS called ANVIRZEL(TM). The drug is an herbal extract which is nontoxic and causes no adverse side effects. Closed clinical trials are showing that the dru
- Interferon Sciences Completes Target Enrollment of Phase 3 Clinical Trial in HIV-Positive Patients
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday May 7, 1997. 10:24 AM EDT
- NEW BRUNSWICK, N.J., May 7 /PRNewswire/ -- Interferon Sciences, Inc. (Nasdaq:IFSC) announced today it has reached the enrollment target of 110 patients in its Phase 3, multi-center clinical trial investigating the potential use of ALFERON N Injection(R) for the treatment of HIV-positive patients. If the results of the
- NEJM Study Finds Triple Combination Therapy With Roxane Laboratories' VIRAMUNE Safe and Effective in HIV-1 Infected Infants and Children
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 7 May 1997.
- ADVANCE FOR RELEASE AT 5:00 PM EDT TODAY/ ADVANCE/ COLUMBUS, Ohio, May 7 /PRNewswire/ -- Triple combination therapy including VIRAMUNE(R) ( nevirapine ), a non-nucleoside reverse transcriptase inhibitor (NNRTI), was shown to be effective and well-tolerated in the treatment of infants and children vertically infected wi
- Interferon Sciences Completes Target Enrollment of Phase 3 Clinical Trial in HIV-Positive Patients
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 7 May 1997.
- NEW BRUNSWICK, N.J., May 7 /PRNewswire/ -- Interferon Sciences, Inc. (Nasdaq: IFSC) announced today it has reached the enrollment target of 110 patients in its Phase 3, multi-center clinical trial investigating the potential use of ALFERON N Injection(R) for the treatment of HIV -positive patients. If the results of th
- Saliva Diagnostic Systems Authorized to Sell Rapid HIV Test in India
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 7 May 1997.
- VANCOUVER, Wash., May 7 /PRNewswire/ -- Saliva Diagnostic Systems, Inc. (Nasdaq: SALV) announced today it has received permission to market and distribute its rapid HIV testing product Sero*Strip HIV (R) in India . SDS expects that in its first year of distribution in India, more than 350,000 Sero*Strip HIV tests wil
- LeukoSite Monoclonal Antibody Blocks HIV Infection in Lab Tests
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 7 May 1997.
- CAMBRIDGE, Mass., May 7 /PRNewswire/ -- A monoclonal antibody to CCR5, a chemokine receptor on T cells, blocked HIV infection of those cells in laboratory tests, it was reported in the May 5 issue of the Journal of Experimental Medicine. CCR5 is one of several co-receptors used by HIV to gain entry to T cells. The resu
- New AIDS Drug Tested in Women With HIV Drug Trough Concentrations Higher in Women Than Men
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 7 May 1997.
- PASADENA, Calif., May 7 /PRNewswire/ -- A segment of a study that included a large number of HIV -infected women revealed that the drug combination of Rescriptor ( delavirdine mesylate tablets) and zidovudine ( AZT ) resulted in a 1.
- Aquila's QS-21 Significantly Enhances Immune Response of DNA Vaccines; Preclinical Data Presented on Two Independent Studies at NCVDG Meeting
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday May 6 4:18 PM EDT
- WORCESTER, Mass., May 6 /PRNewswire/ -- Two independent preclinical studies presented today at the 9th Annual meeting of the National Cooperative Vaccine Development Group for AIDS (NCVDG) demonstrated that Aquila Biopharmaceuticals, Inc. s (Nasdaq:AQLA) QS-21 adjuvant significantly enhances the immune response of DNA
- American Foundation For AIDS Research (AmFAR) Receives $220,000 Grant From Bristol-Myers Squibb Foundation to Support National Women's AIDS Clinical Trial Recruitment Program
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday May 6 5:23 PM EDT
- NEW YORK, May 6 /PRNewswire/ -- By the year 2000, the World Health Organization estimates that HIV-positive women will outnumber HIV-positive men by 20 percent. In response to these alarming statistics, the Bristol-Myers Squibb Foundation today announced that it has formed a partnership with the American Foundation for
- SmithKline Beecham's Testosterone Replacement Therapy Now Available As Convenient 5 Mg Single Patch System
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 5 May 1997.
- PHILADELPHIA, and SALT LAKE CITY, May 5 /PRNewswire/ -- SmithKline Beecham (NYSE: SBH) and TheraTech, Inc. (Nasdaq: THRT) announced that a new 5 milligram per day formulation of Androderm(R) (Testosterone Transdermal System), has been cleared for marketing by the U.S. Food and Drug Administration ( FDA ).
- Determination Marks Opening of Third National Conference on Women & HIV
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday May 5, 1997, 1:43 PM EDT
- PASADENA, Calif., May 5 /PRNewswire/ -- A key immunologist at the third National Conference on Women & HIV finally confirmed what women have suspected all along. There is an urgent need to study women and HIV because scientists cannot assume that what is true for men is true for women. During the May 4 opening of t
- HGP-30 AIDS Vaccine Shows Recognition of Major HIV Subtypes in Human and Animal Studies
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday May 5, 1997. 8:32 AM EDT
- ALEXANDRIA, Va., May 5 /PRNewswire/ -- CEL-SCI Corporation (Nasdaq:CELI) announced the presentation of data which shows that CEL-SCI s HGP-30 HIV vaccine induced antibodies in humans and in mice that recognize the corresponding regions of the HIV subtypes B, C and E. The HGP-30 vaccine is copied from a region of the HI
- National Conference on Women and HIV to Address Major Gaps in Research, Policy, Treatment and Prevention Efforts; Experts Gather to Explore why American Women are Fastest Growing Group with New HIV Infections and Why AIDS is Now Their Third Leading Cause of Death
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday May 5, 1997, 5:51 AM EDT
- LOS ANGELES, May 5 /PRNewswire/ -- Over 1,500 scientists, women with HIV infection, and prevention and policy experts in HIV/AIDS are gathering to explore the most recent developments at the National Conference on Women and HIV, opening today in Los Angeles. In an effort to understand why women are the fastest growing
- Hybridon Expands AIDS Research Through Collaboration With Robert Gallo's New Institute of Human Virology
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday May 1, 1997, 2:20 PM EDT
- CAMBRIDGE, Mass., and BALTIMORE, Md., May 1 /PRNewswire/ -- Hybridon (Nasdaq:HYBN) and the Institute of Human Virology today announced the signing of a five-year research collaboration. The agreement will cover a continuation of the development of oligonucleotide-based antisense therapies targeting HIV and AIDS with an
- LXR Biotechnology Inc. Announces Completion of Phase I Trials for Lexirin; Phase I/II Trials Expected to Begin During the Second Quarter of 1997
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 1 May 1997.
- RICHMOND, Calif., May 1 /PRNewswire/ -- LXR Biotechnology (AMEX: LXR), the first biopharmaceutical company to advance drug candidates for the modulation of apoptosis (genetically programmed death of cells), announced the achievement of an important clinical development milestone. LXR revealed completion of Phase I tri
- Maxim Initiates Clinical Trial In Hepatitis C
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 1 May 1997.
- SAN DIEGO, May 1 /PRNewswire/ -- Maxim Pharmaceuticals, Inc. (AMEX: MMP) today announced that it has initiated a clinical trial of its drug, Maxamine(TM), for the treatment of hepatitis C. The prevalence of hepatitis C is estimated to be 4 million people in the United States and up to 120 million worldwide. Current l
- Immunomedics Seeks FDA Approval for Evaluation of Humanized Antibody in Therapy of Non-Hodgkin's Lymphomas
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 1 May 1997.
- MORRIS PLAINS, N.J., May 1 /PRNewswire/ -- Immunomedics, Inc. (Nasdaq: IMMU) announced today that it has filed an application with the U.S. Food and Drug Administration ( FDA ) to begin a clinical evaluation of the safety and efficacy of its humanized lymphoma antibody, LymphoCide(TM). The Phase I dose-escalation tri
- Senetek files Product Licensing Application, seeking approval to market its INVICORP therapy for erectile dysfunction; Clinical data suggest INVICORP is more efficacious than MUSE(R) and Viagra(TM)
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 30 April 1997.
- NEW YORK, April 30 /PRNewswire/ -- Senetek PLC (Nasdaq: SNTKY) announced today that it has filed a Product Licensing Application (PLA) with the United Kingdom s Medicines Control Agency (MCA) seeking approval to market its new drug therapy for treating moderate-to-severe, organic-based erectile dysfunction (ED) in male
- Midwest AIDS Prevention Project: Ann Arbor Fights AIDS - One Step at a Time; Fifth Anniversary 'Ann Arbor Aid for AIDS' Walkathon to be Held Saturday, June 14
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 29 April 1997.
- ANN ARBOR, Mich., April 29 /PRNewswire/ -- People of all ages will don their favorite walking shoes on Saturday, June 14, at 9:30 a.m., when the fifth annual Ann Arbor Aid for AIDS fundraising pledge walk begins, reports the Midwest AIDS Prevention Project. Walkers will trek through downtown Ann Arbor, beginning and e
- Agouron Acquires Alanex Corporation
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 29 April 1997.
- LA JOLLA, Calif., April 29 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. (Nasdaq-NNM: AGPH) announced today that it has signed a definitive agreement to acquire Alanex Corporation, a privately held drug discovery company, for 1,000,000 shares of newly issued Agouron common stock. The transaction is expected to close i
- Alpharma Announces FDA Approval for Acyclovir Oral Suspension; First Generic Equivalent and Only Liquid Product
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 29 Apri 1997.
- FORT LEE, N.J., April 29 /PRNewswire/ -- Alpharma Inc. (NYSE: ALO) today announced that its U.S. Pharmaceuticals Division (USPD) received approval from the Food and Drug Administration to manufacture and market Acyclovir Oral Suspension. Acyclovir is the generic equivalent of the branded product
- The Medicine Shoppe Pharmacy system launches consumer education campaign 1,100 community pharmacists lead awareness effort
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday April 28 12:01 PM EDT
- ST. LOUIS--(BW HealthWire)--April 28, 1997--American consumers have long held pharmacists in high esteem, ranking them first among the most trusted professions. For eight consecutive years, the Gallup Poll rated pharmacists number one in honesty and ethical standards, ahead of physicians and preachers. Now consumers wi
- Philadelphia AIDS Consortium Spends Over $200,000 for Viral Load Testing
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday April 25 6:25 PM EDT
- PHILADELPHIA, April 25 /PRNewswire/ -- The Philadelphia AIDS Consortium today issued the following statement: In the past four months, The Philadelphia AIDS Consortium has provided over $200,000 in viral load tests to consumers who could not otherwise afford them. These funds were provided through a combination of Titl
- International Murex's SUDS HIV Sales Reach Record High; Murex's SUDS HIV Test Remains the Only FDA Approved Rapid EIA Assay
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday April 25 12:10 PM EDT
- TORONTO, April 25 /PRNewswire/ -- International Murex Technologies Corporation (Nasdaq:MURXF - news) today announced that its SUDS(R) HIV test realized record sales of over one-half-a-million dollars during the month of March 1997. In the United States , sales of the SUDS HIV test increased 62% during the month. Requir
- New From ESI Lederle - Acyclovir 400 mg & 800 mg Tablets
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, April 24, 1997 13:45
- PHILADELPHIA, April 24 /PRNewswire/ -- ESI Lederle, a division of Wyeth-Ayerst Laboratories, announced today the availability of Acyclovir 400 mg and 800 mg Tablets. These new strengths complete the comprehensive line of ESI Lederle oral Acyclovir products, which will provide physicians and patients with the convenien
- State AIDS Drug Assistance Programs Will Need an Additional $131.7 Million in Federal Funding for FY 1998 to Provide Cost-Effective Combination Drug Therapy To Patients in Need, Expert Group Tells Congress; Extensive Data on Favorable Impact of New Drug Regimens on AIDS Death Rates, Hospital and Hospice Admissions and Incidence of Costly Opportunistic Infections More Than Justifies Additional Funds for These Therapies, Doctors and Patient Advocates Say
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday April 17 12:00 PM EDT
- WASHINGTON, April 17 /PRNewswire/ -- The ADAP Working Group, a unique coalition of AIDS advocacy organizations and research-based pharmaceutical and biotechnology organizations, today presented preliminary data from a national survey of State AIDS Drug Assistance Programs (ADAPs) suggesting that for FY 1998, combined F
- Extensive Data on Favorable Impact of New Drug Regimens on AIDS Death Rates, Hospital and Hospice Admissions and Incidence of Costly Opportunistic Infections More Than Justifies Additional Funds for These Therapies, Doctors and Patient Advocates Say
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 17 April 1997.
- WASHINGTON, April 17 /PRNewswire/ -- The ADAP Working Group, a unique coalition of AIDS advocacy organizations and research-based pharmaceutical and biotechnology organizations, today presented preliminary data from a national survey of State AIDS Drug Assistance Programs (ADAPs) suggesting that for FY 1998, combined F
- Researchers Report Success Using Gene Therapy To Protect Human Cells From AIDS Virus
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday April 17 8:20 AM EDT
- FARMINGDALE, N.Y., April 17 /PRNewswire/ -- Scientists have successfully used gene therapy to produce human immune (CD4+) cells in the laboratory with resistance to repeated challenges by HIV over a prolonged period, it was reported in the May edition of the Journal of Virology, the peer-reviewed journal of the America
- Harvard and Hybridon Researchers Report In Vitro Results Of Mechanism of Action of GEM 91 and its Resistance Profile
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday April 17 9:28 AM EDT
- CAMBRIDGE, Mass., April 17 /PRNewswire/ -- In a paper published today in AIDS Research and Human Retroviruses (volume 13, No.7), scientists from Harvard Medical School and Hybridon, Inc. (Nasdaq:HYBN) describe the novel anti-HIV activity of GEM(R)91, Hybridon s genetic antisense drug which is currently in a confirmator
- Experts Will Explain How Investment in Treatment with Combination Drug Therapy Including Protease Inhibitors has Saved Lives and Reduced Hospital, Hospice and Medical Specialist Costs by Millions of Dollars
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 17 April 1997.
- AIDS advocate Mary Fisher, a featured speaker at the 1992 and 1996 Republican National Conventions, will keynote a Congressional Education Seminar on The Promise of New AIDS Treatments and the Crisis in Access, Thursday, April 17, in Rooms B-339/340, Rayburn House Office Building, noon- 1:30 p.m. The event, hosted by S
- Mechanism of Novel Tumor Necrosis Factor -Alpha Inhibitors Identified
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 16 April 1997.
- SANTA FE, N.M., April 16 /PRNewswire/ -- New compounds from Celgene Corporation (Nasdaq: CELG) appear to have a highly specific inhibitory effect on the phosphodiesterase type 4 enzyme (PDE-4), which reduces overproduction of tumor necrosis factor -alpha (TNF -alpha). The laboratory data provided new confirmation that
- 'AIDS Watch' Participants Gather From 32 States Calling for Congressional Support of HIV/AIDS Programs; Representative Nancy Pelosi Joins Rally to Focus Congressional Discussion On Need for Increased Funding
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday April 15 9:01 AM EDT
- WASHINGTON, April 15 /PRNewswire/ -- Hundreds participating in this year s AIDS Watch were joined by Representative Nancy Pelosi (D-CA) at a rally this morning at the House Triangle calling for increased funding of HIV/AIDS programs in the areas of prevention, care, treatment, research and housing. United not only in a
- PNT Technology To Be Used In Production of Advanced Chemistries for Genetic Drugs
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 15 April 1997.
- CAMBRIDGE, Mass., April 15 /PRNewswire/ -- Hybridon (Nasdaq: HYBN) today announced the issuance of US Patent No. 5,614,622 for the composition of matter of pent-enoyl (PNT) protected nucleotides which facilitate the rapid synthesis of synthetic DNA and the production of a variety of DNA analogs. The Company expects tha
- Study Shows Decrease in Risk of Death and Disease Progression in Patients with HIV
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 14 April 1997.
- RESEARCH TRIANGLE PARK, N.C., April 14 /PRNewswire/ -- On the strength of an international study which recently showed Epivir (TM) (lamivudine; 3TC ) to be effective in reducing the risk of death and disease progression in persons with AIDS, the Food and Drug Administration has released the d
- FRC Speaks Out Against Drug Legalization and Needle Exchange at Swiss Conference
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 11 April 1997.
- WASHINGTON, April 11 /PRNewswire/ -- As our nation flirts with the idea of medical marijuana and toys with failed needle exchange programs, it is clear that the U.S. is following the Swiss example on drug policy, Family Research Council s Senior Policy Analyst Robert Maginnis said Friday. That s why it s so appropriate
- Viracept Combination Therapy Drops HIV Below Quantifiable Levels in Both Blood and Lymph Tissue
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday April 11 8:13 AM EDT
- LA JOLLA, Calif., April 11 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. (Nasdaq-NMM: AGPH) today announced results from an ongoing study in which HIV remained below quantifiable levels in both the plasma and lymphoid tissue of chronically infected patients tested after one year of combination therapy consisting of VIR
- Lifesaving UNAIDS Shipments of Female Condoms Start, Reports The Female Health Company
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 10 April 1997.
- CHICAGO, April 10 /PRNewswire/ -- The first of many, potentially lifesaving, shipments of the female condoms left the U.K. yesterday (Wednesday, April 9) to help hundreds of thousands of women currently at risk from HIV in Africa. The departure of the consignment of over 100,000 female condoms marks the start of a majo
- April is Workout for Hope Month! 216 Million 'Steps' Closer to a Cure for HIV/AIDS and Related Cancers; 9th Annual Workout for Hope... for the Body and Soul
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 10 April 1997.
- LOS ANGELES, April 10 /PRNewswire/ -- April is Workout for Hope Month as 20,000 fitness enthusiasts take 216 million steps toward a cure for HIV/AIDS and related cancers in the 9th annual Workout for Hope being held in 70 cities during April, most on April 19, 1997. To register, or for information about your city s Wor
- Statement From Loyola Law School
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 15 April 1997.
- LOS ANGELES, April 9 /PRNewswire/ -- Following testing for tuberculosis among approximately 120 students and staff at Loyola Law School on Monday, April 7, 1997, it was subsequently discovered that there was a possibility that needles used in the test procedures may have been used more than once. Every effort is now be
- PPMs Moving Into The Clinical Trials Industry
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 8 April 1997.
- BOSTON, April 8 /PRNewswire/ -- In its April issue, CenterWatch is reporting that some physician practice management companies are developing clinical-trial programs throughout their networks. The PPMs pursuing this strategic initiative are promising to provide pharmaceutical companies with access to large numbers of p
- UTMB: New Two-Drug HIV Therapy Shown to Be Safe, Effective
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 8 April 1997.
- ADVANCE FOR RELEASE 11:45 A.M. EDT TUESDAY, APRIL 8/ ADVANCE/ ATLANTA, April 8 /PRNewswire/ -- A new therapy combining two familiar AIDS medicines has been shown to be a safe, effective alternative to more complicated therapies. A new study that followed patients for one year suggests that the treatment -- a combinatio
- FDA Clears Hybridon's IND For New Drug To Combat Systemic CMV In Immunocompromised Patients; Clinical and Preclinical Data on GEM(R)132 Presented at International Conference
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 7 April 1997.
- CAMBRIDGE, Mass., April 7 /PRNewswire/ -- Hybridon, Inc. (Nasdaq: HYBN) today announced that the FDA has cleared the Company s application to begin human clinical trials for the systemic use of GEM(R)132, a new drug to treat cytomegalovirus ( CMV ) infections via IV admi
- Pharmacia & Upjohn Announced New Aids Drug Receives FDA Marketing Clearance
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 7 April 1997.
- LONDON, April 7 /PRNewswire/ -- Pharmacia & Upjohn (NYSE: PNU) (P&U) announced today that the United States Food and Drug Administration ( FDA ) has granted the company marketing clearance for Rescriptor Tablets (
- Triangle Pharmaceuticals Exercises Option to Acquire MKC-442
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday 7 April 1997.
- DURHAM, N.C., April 7 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) announced today that it has exercised its option to acquire a license from Mitsubishi Chemical Corporation for the rights to MKC-442 worldwide except in certain East Asian countries, including Japan , Chi
- Agouron Reports Anti-HIV Effects of VIRACEPT After Ten Months of Combination Therapy
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 7 April 1997.
- LA JOLLA, Calif., April 7 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. (Nasdaq-NNM: AGPH) reported that profound anti-HIV effects from its protease inhibitor VIRACEPT(R) (nelfinavir mesylate), when taken in combination with other anti-HIV drugs, continue to be observed after ten months of treatment. VIRACEPT was recen
- Quick Response By State Officials Contains Hepatitis A Outbreak
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 3 April 1997.
- LANSING, Mich., April 3 /PRNewswire/ -- Health officials in Michigan continue to address the recent outbreak of hepatitis A and its link to frozen strawberries distributed through the United States Department of Agriculture (USDA) school lunch program. We have worked aggressively with local health departments and the C
- Hybridon Unblinds Clinical Trial Results Of GEM 91 Showing Activity Against Advanced HIV;Up to 90% Decreases in Cellular Viremia Observed In HIV-Positive Patients
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday April 3 1997 - 3:32 PM EDT
- CAMBRIDGE, Mass., April 3 /PRNewswire/ -- Hybridon Inc today reported the unblinded results of the three highest dose levels of its Phase Ib/II clinical trial of GEM(R) 91, the first genetic antisense drug designed to attack the HIV genome. The analysis revealed a substantial decrease in cellular viremia levels of up t
- Hepatitis C: The Silent Killer, Everyone May Be At Risk
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 3 April 1997.
- WARMINSTER, Pa., April 3 /PRNewswire/ -- Recent media attention to the hepatitis C epidemic may have given Americans a false sense of security that the disease is one of intravenous drug users and sexually promiscuous people only, according to Stephen P. Longello, Executive Director of the Hepatitis C Foundation. IV dr
- FAST FACTS ABOUT HEPATITIS: Hepatitis A Strikes Hardest In Older Individuals
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday 2 April 1997.
- WEST POINT, Pa., April 2 /PRNewswire/ -- Even in areas where hepatitis A is common, Americans tend to underestimate its risks, according to a Gallup survey. The survey was commissioned by Merck & Co. , Inc. The company makes a vaccine indicated for hepatitis A. According to the Federal Centers for Disease Control a
- Fast Facts About Hepatitis A
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 2 April 1997.
- WEST POINT, Pa., April 2 /PRNewswire/ -- The following was released today by Merck & Co. : Hepatitis A -- What Is It? Hepatitis A (HAV) is a highly contagious virus that attacks the liver. It is the seventh most commonly reported infectious disease in the United States (behind gonorrhea, chicken pox, sy
- IVAX Corporation And NaPro BioTherapeutics Announce Submission Of New Drug Application For Paclitaxel; IVAX' Paxene(TM) Brand Paclitaxel Targets AIDS-Related Cancer
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 1 April 1997.
- MIAMI and BOULDER, Colo., April 1 /PRNewswire/ -- IVAX Corporation (AMEX: IVX) and NaPro BioTherapeutics, Inc. (Nasdaq: NPRO) today announced that IVAX has submitted a New Drug Application to the U.S. Food and Drug Administration seeking clearance to market Paxene(TM) in the U.S. for the treatment of Kaposi s sarcoma,
- Durex Sheik Online Survey Shows Condoms Less Likely, High Risk Behavior More Common at Spring Break
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 1 April 1997.
- PANAMA CITY BEACH, Fla., April 1 /PRNewswire/ -- According to a Durex Sheik online survey of Panama City Beach spring breakers, college students are actually less sexually active during spring break than they are back on campus, despite long-standing perceptions to the contrary. That s the good news. The bad news is th
- Digene Introduces New HPV DNA Test At Eurogin 97 Third International Congress
- PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 27 March 1997.
- PARIS, March 27 /PRNewswire/ -- Digene Corpor